UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

or

□ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ____

Commission file number: 001-38273



ACM Research, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation or Organization)

42307 Osgood Road, Suite I Fremont, California

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (510) 445-3700

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on which Registered				
Class A Common Stock, \$0.0001 par value	ACMR	The NASDAQ Stock Market LLC				

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗹 No 🗖

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	\checkmark	Accelerated filer	
Non-accelerated filer		Smaller reporting company	
		Emerging growth company	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 🗆 No 🗹

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date.

Class	Number of Shares Outstanding
Class A Common Stock, \$0.0001 par value	56,986,777 shares outstanding as of May 3, 2024
Class B Common Stock, \$0.0001 par value	5,021,811 shares outstanding as of May 3, 2024

94-3290283

(I.R.S. Employer Identification No.)

94539

(Zip Code)

TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION	4
Item 1.	Financial Statements (unaudited)	4
	Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023	4
	Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2024 and 2023	5
	Condensed Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2024 and 2023	6
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023	7
	Notes to the Condensed Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	35
Item 3.	Quantitative and Qualitative Disclosures about Market Risks	53
Item 4.	Controls and Procedures	53
PART II.	OTHER INFORMATION	54
Item 1.	Legal Proceedings	54
Item 1A.	Risk Factors	55
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	55
Item 3.	Defaults Upon Senior Securities	57
Item 4.	Mine Safety Disclosures	57
Item 5.	Other Information	55
Item 6.	<u>Exhibits</u>	57
Signatures		58

ACM Research, Inc., or ACM Research, is a Delaware corporation founded in California in 1998 to supply capital equipment developed for the global semiconductor industry. Since 2005, ACM Research has conducted its business operations principally through its subsidiary ACM Research (Shanghai), Inc., or ACM Shanghai, a limited liability corporation formed by ACM Research in the People's Republic of China, or mainland China, in 2005. Unless the context requires otherwise, references in this report to "our company," "our," "us," "we" and similar terms refer to ACM Research, Inc. and its subsidiaries, including ACM Shanghai, collectively.

We conduct a substantial majority of our product development, manufacturing, support and services in mainland China through ACM Shanghai. We are not a mainland China operating company, and we do not conduct our operations in mainland China through the use of a variable interest entity or any other structure designed for the purpose of avoiding mainland China legal restrictions on direct foreign investments in mainland China-based companies. For a description of certain matters relating to our operations in mainland China, including our corporate structure, the movement of cash throughout our organization, certain audit and regulatory matters, and risks associated therewith, please see "Item 2—Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report, the disclosure at the forefront of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Risk Factors included therein, as referenced or updated by the disclosure included in "Part II. Item 1A—Risk Factors" in this report.

For purposes of this report, certain amounts in Renminbi, or RMB, have been translated into U.S. dollars solely for the convenience of the reader. The translations have been made based on the conversion rates published by the State Administration of Foreign Exchange of the People's Republic of China.

SAPS, TEBO, ULTRA C, ULTRA Fn, Ultra ECP, Ultra ECP map, and Ultra ECP ap are trademarks of ACM Research. For convenience, these trademarks appear in this report without TM symbols, but that practice does not mean that ACM Research will not assert, to the fullest extent under applicable law, ACM Research's rights to the trademarks. This report also contains other companies' trademarks, registered marks and trade names, which are the property of those companies.

FORWARD-LOOKING STATEMENTS AND STATISTICAL DATA

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors, including those described or incorporated by reference in "Item 1A. Risk Factors" of Part II of this report, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

The information included under the heading "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations – Overview," of Part I of this report contains statistical data and estimates, including forecasts, that are based on information provided by Gartner, Inc., or Gartner, in "Forecast: Semiconductor Wafer Fab Equipment, Worldwide, 4Q23 Update" (December 2023), or the Gartner Report. The Gartner Report represents research opinions or viewpoints that are published, as part of a syndicated subscription service, by Gartner and are not representations of fact. The Gartner Report speaks as of its original publication date (and not as of the date of this report), and the opinions expressed in the Gartner Report are subject to change without notice. While we are not aware of any misstatements regarding any of the data presented from the Gartner Report, estimates, and in particular forecasts, involve numerous assumptions and are subject to risks and uncertainties, as well as change based on various factors, that could cause results to differ materially from those expressed in the data presented below.

Any forward-looking statement made by us in this report speaks only as of the date on which it is made. Except as required by law, we assume no obligation to update these statements publicly or to update the reasons actual results could differ materially from those anticipated in these statements, even if new information becomes available in the future.

You should read this report, and the documents that we reference in this report and have filed as exhibits to this report, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ACM RESEARCH, INC. Condensed Consolidated Balance Sheets (In thousands, except per share data)

]	March 31, 2024		December 31, 2023	
Assets	(Unaudited)			
Current assets:					
Cash and cash equivalents (note 2)	\$	211,305	\$	182,090	
Restricted cash		808		1,083	
Short-term time deposits (note 2)		48,364		80,524	
Short-term investments (note 15)		18,648		21,312	
Accounts receivable, net (note 4)		296,371		283,186	
Other receivables		51,316		40,065	
Inventories, net (note 5)		581,140		545,395	
Advances to related party (note 16)		1,338		2,432	
Prepaid expenses		20,066		20,023	
Total current assets		1,229,356		1,176,110	
Property, plant and equipment, net (note 6)		218,822		201,848	
Land use right, net (note 7)		8,305		8,367	
Operating lease right-of-use assets, net (note 11)		6,498		7,026	
Intangible assets, net		2,803		2,538	
Long-term time deposits (note 2)		27,841		40,818	
Deferred tax assets (note 19)		21,360		20,271	
Long-term investments (note 14)		31,293		27,880	
Other long-term assets (note 8)		10,471		6,050	
Total assets	\$	1,556,749	\$	1,490,908	
Liabilities and Equity					
Current liabilities:					
Short-term borrowings (note 9)	\$	54,706	\$	31,335	
Current portion of long-term borrowings (note 12)		6,549		6,783	
Related party accounts payable (note 16)		16,243		11,407	
Accounts payable		135,499		141,814	
Advances from customers (note 3)		182,547		181,368	
Deferred revenue (note 3)		4,405		3,687	
Income taxes payable (note 19)		11,403		6,401	
FIN-48 payable (note 19)		12,131		12,149	
Other payables and accrued expenses (note 10)		107,098		102,951	
Current portion of operating lease liabilities (note 11)		2,668		2,764	
Total current liabilities		533,249		500,659	
Long-term borrowings (note 12)		53,408		53,952	
Long-term operating lease liabilities (note 11)		3,830		4,262	
Other long-term liabilities (note 13)		5,469		5,873	
Total liabilities		595,956		564,746	
Commitments and contingencies (note 21)		575,750		501,710	
Equity:					
Stockholders' equity:					
Class A Common stock (note 17)		6		6	
Class B Common stock (note 17)		1		1	
Additional paid-in capital		646,800		629,845	
Retained earnings				156,827	
Statutory surplus reserve (note 22)		174,260 30,060		30,060	
Accumulated other comprehensive loss		(54,925)		(49,349)	
Total ACM Research, Inc. stockholders' equity		796,202		767,390	
Non-controlling interests		164,591		158,772	
Total equity		960,793	•	926,162	
Total liabilities and equity	\$	1,556,749	\$	1,490,908	

The accompanying notes are an integral part of these condensed consolidated financial statements.

ACM RESEARCH, INC.

Condensed Consolidated Statements of Comprehensive Income

(In thousands, except share and per share data) (Unaudited)

	Three Months Ended March 31,			
		2024		2023
Revenue (note 3)	\$	152,191	\$	74,256
Cost of revenue, including cost of revenue from related parties of \$15.1 million and \$18.4 million for the three months ended March 31, 2024 and 2023, respectively (note 16)		73,070		34,270
Gross profit		79,121		39,986
Operating expenses:				
Sales and marketing		14,173		9,337
Research and development		23,918		14,029
General and administrative		15,798		7,758
Total operating expenses		53,889		31,124
Income from operations		25,232		8,862
Interest income		1,774		1,785
Interest expense		(783)		(695)
Realized gain from sale of short-term investments (note 15)		273		3,994
Unrealized loss on short-term investments (note 15)		(2,595)		(654)
Other income (expense), net		3,080		(1,418)
Loss from equity method investments (note 14)		(520)		(32)
Income before income taxes		26,461		11,842
Income tax expense (note 19)		(4,369)		(2,879)
Net income		22,092		8,963
Less: Net income attributable to non-controlling interests		4,659		1,818
Net income attributable to ACM Research, Inc.	\$	17,433	\$	7,145
Comprehensive income:				
Net income		22,092		8,963
Foreign currency translation adjustment, net of tax		(6,829)		9,423
Comprehensive income		15,263		18,386
Less: Comprehensive income attributable to non-controlling interests		3,406		3,462
Comprehensive income attributable to ACM Research, Inc.	\$	11,857	\$	14,924
Net income attributable to ACM Research, Inc. per share of common stock (note 2):				
Basic	\$	0.28	\$	0.12
Diluted	\$	0.26	\$	0.11
Weighted average shares of common stock outstanding used in computing per share amounts (note 2):				
Basic		61,367,184		59,736,764
Diluted		66,242,321		65,058,777

The accompanying notes are an integral part of these condensed consolidated financial statements.

ACM RESEARCH, INC. Condensed Consolidated Statements of Changes in Equity For the Three Months Ended March 31, 2024 and 2023

(In thousands, except share and per share data)

(Unaudited)

	Com Stock C		Com Stock (mon Class B						
	Shares	Amount	Shares	Amount	Additional Paid- in Capital	Retained Earnings	Statutory Surplus Reserve	Accumulated Other Comprehensive Income (Loss)	Non- controlling Interests	Total Equity
Balance at December 31, 2022	54,655,286	\$ 5	5,021,811	\$ 1	\$ 604,089	\$ 94,426	\$ 16,881	\$ (40,546)	\$ 137,315	\$ 812,171
Cumulative effect of change in accounting principle under ASC 326, net of tax	_	_	_	_	_	(1,769)	_	-	_	(1,769)
Net income	-	-	-	-	-	7,145	-	_	1,818	8,963
Foreign currency translation adjustment	-	_	_	_	-	_	-	7,778	1,645	9,423
Exercise of stock options	163,069	-	-	-	241	-	-	-	-	241
Stock-based compensation	-	-	-	-	2,068	-	-	-	-	2,068
Balance at March 31, 2023	54,818,355	\$ 5	5,021,811	\$ 1	\$ 606,398	\$ 99,802	\$ 16,881	\$ (32,768)	\$ 140,778	\$ 831,097

	Comn Stock Cl		Comr Stock C							
	Shares	Amount	Shares	Amount	- Additional Paid- in Capital	Retained Earnings	Statutory Surplus Reserve	Accumulated Other Comprehensive Loss	Non- controlling Interests	Total Equity
Balance at December 31, 2023	56,036,172 \$	6 6	5,021,811 \$	\$1	\$ 629,845	\$ 156,827	\$ 30,060	\$ (49,349)	\$ 158,772 \$	926,162
Net income	-	-	-	-	-	17,433	-	-	4,659	22,092
Foreign currency translation adjustment	-	-	-	-	-	-	-	(5,576)	(1,253)	(6,829)
Exercise of stock options	950,605	-	-	-	4,799	-	-	-	-	4,799
Stock-based compensation	-	-	-	-	12,156	-	-	-	2,413	14,569
Balance at March 31, 2024	56,986,777 \$	56	5,021,811 9	\$1	\$ 646,800	\$ 174,260	\$ 30,060	\$ (54,925)	\$ 164,591 \$	960,793

The accompanying notes are an integral part of these condensed consolidated financial statements.

ACM RESEARCH, INC. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited)

	Three Months Ended March 31,			
		2024		2023
Cash flows from operating activities:				
Net income	\$	22,092	\$	8,963
Adjustments to reconcile net income from operations to net cash used in operating activities				
Non-cash operating lease cost		973		488
Depreciation and amortization		2,518		1,714
Realized gain on short-term investments		(273)		(3,994
Loss from equity method investments		520		32
Unrealized loss on short-term investments		2,595		654
Inventory provision		1,025		306
Provision for credit losses		1,171		298
Deferred income taxes		(1,129)		(6,294
Stock-based compensation		14,569		2,068
Net changes in operating assets and liabilities:		<u> </u>		,
Accounts receivable		(15,286)		(2,452)
Other receivables		(11,580)		(5,423
Inventories		(38,574)		(80,248
Advances to related party (note 16)		1,094		1,016
Prepaid expenses		(141)		(3,362
Related party accounts payable (note 16)		4,836		3,886
Accounts payable		(5,553)		13,250
Advances from customers		2,182		25,857
Deferred revenue		4,892		3,407
		4,892 5,009		6,683
Income taxes payable				0,083
FIN-48 payable		(19)		
Other payables and accrued expenses		807		1,327
Operating lease liabilities		(973)		(488
Other long-term liabilities		(404)		1,730
Net cash used in operating activities		(9,649)		(30,494
Cash flows from investing activities:				
Purchase of property and equipment	\$	(25,419)		(14,895)
Purchase of intangible assets		(668)		(155)
Purchase of short-term investments (note 15)		(1,409)		(728
Purchase of time deposits		(45,270)		(14,120
Proceeds from maturity of time deposits		90,445		67,955
Proceeds from sale of short-term investments (note 15)		_		11,072
Purchase of long-term investments (note 14)		(5,988)		
Dividends from unconsolidated affiliates		600		
Net cash provided by investing activities		12,291		49,129
The cash provided by investing activities		12,271		19,129
Cash flows from financing activities:				
Proceeds from short-term borrowings		23,530		
Repayments of short-term borrowings		(287)	\$	
Repayments of long-term borrowings		(1,193)	*	(1,696
Proceeds from exercise of stock options		4,799		241
Net cash provided by (used in) financing activities		26,849		(1,455
the cash provided by (ased in) maneing activities		20,017		(1,755)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	\$	(551)	\$	(4,784
Net increase in cash, cash equivalents and restricted cash	\$	28,940	\$	12,396

Cash, cash equivalents and restricted cash at beginning of period	183,173	248,451
Cash, cash equivalents and restricted cash at end of period	\$ 212,113	\$ 260,847
Supplemental disclosure of cash flow information:		
Interest paid, net of capitalized interest	\$ 783	\$ 695
Cash paid for income taxes	\$ 	\$ 2,874
Reconciliation of cash, cash equivalents and restricted cash in consolidated statements of cash flows:		
Cash and cash equivalents	\$ 211,305	\$ 260,387
Restricted cash	808	460
Cash, cash equivalents and restricted cash	\$ 212,113	\$ 260,847
Non-cash financing activities:		
Cashless exercise of stock options	\$ 140	\$ 47
Non-cash investing activities:		
Proceeds from sale of short-term investments included in other receivables	\$ 3,167	\$
Transfer from inventory to property, plant and equipment	\$ 	\$ 4,557
Transfer of prepayment for property to property, plant, and equipment	\$ 5,320	\$ 161

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTE 1 – DESCRIPTION OF BUSINESS

ACM Research, Inc. ("ACM" or "ACM Research") and its subsidiaries (collectively with ACM, the "Company") develop, manufacture and sell capital equipment to the global semiconductor industry.

ACM was incorporated in California in 1998, and it initially focused on developing tools for manufacturing process steps involving the integration of ultra low-K materials and copper. The Company's early efforts focused on stress-free copper-polishing technology, and it sold tools based on that technology in the early 2000s.

In 2006, the Company established its operational center in Shanghai in the People's Republic of China ("mainland China"), where it operates through ACM's subsidiary, ACM Research (Shanghai), Inc. ("ACM Shanghai"). ACM Shanghai was formed to help establish and build relationships with integrated circuit manufacturers in mainland China, and the Company initially financed its Shanghai operations in part through sales of non-controlling equity interests in ACM Shanghai.

In 2007, the Company began to focus its development efforts on single-wafer wet-cleaning solutions for the front-end chip fabrication process. The Company introduced its SAPS megasonic technology, which can be applied in wet wafer cleaning at numerous steps during the chip fabrication process, in 2009. It introduced its TEBO technology, which can be applied at numerous steps during the fabrication of small node two-dimensional conventional and three-dimensional patterned wafers, in March 2016. The Company has designed its equipment models for SAPS and TEBO solutions using a modular configuration that enables it to create a wet-cleaning tool meeting the specific requirements of a customer, while using pre-existing designs for chamber, electrical, chemical delivery and other modules. In 2018, the Company introduced its Ultra-C Tahoe wafer cleaning tool, which can deliver high cleaning performance with significantly less sulfuric acid than typically consumed by conventional high-temperature single-wafer cleaning tools. In 2020, the Company introduced a range of semi-critical cleaning systems, extending its products to support additional less demanding but still important production steps to semiconductor manufacturers.

Based on its electro-chemical plating ("ECP") technology, the Company introduced in 2019 its Ultra ECP ap, or "Advanced Packaging," tool for bumping, or applying copper, tin and nickel to semiconductor wafers at the die-level, and its Ultra ECP map, or "Multi-Anode Partial Plating," tool to deliver advanced electrochemical copper plating for copper interconnect applications in front-end wafer fabrication processes. In 2022, the Company added two major new product categories with the introduction of the Ultra PmaxTM PECVD and Ultra Track tools. The Company also offers a range of custom-made equipment, including cleaning, coaters and developers, to back-end wafer assembly and packaging factories, principally in mainland China.

In November 2016, ACM re-domesticated from California to Delaware pursuant to a merger in which ACM Research, Inc., a California corporation, was merged into a newly formed, wholly-owned Delaware subsidiary, also named ACM Research, Inc.

In November 2021, ACM Shanghai completed its STAR Listing and STAR IPO and its shares began trading on the STAR Market. In the STAR IPO, ACM Shanghai issued 43,355,753 shares, representing 10% of the total 433,557,100 shares outstanding after the issuance. The shares were issued at a public offering price of RMB 85.00 per share, and the net proceeds of the STAR IPO, after issuance costs, totaled \$545,512. Upon completion of the STAR IPO, ACM owned 82.5% of the outstanding ACM Shanghai shares. However, in May 2023, ACM's ownership declined to 82.1% due to the exercise of 2,150,309 stock options related to ACM Shanghai shares.

The Company has direct or indirect interests in the following subsidiaries:

			Effective intere	est held as at
Name of subsidiaries	Place and date of incorporation	Principal Activities	March 31, 2024	December 31, 2023
ACM Research (Shanghai), Inc. ("ACM Shanghai")	Mainland China, May 2005	Principal operating subsidiary	82.1 %	82.1 %
ACM Research (Wuxi), Inc. ("ACM Wuxi")	Mainland China, July 2011	Sales and services	82.1 %	82.1 %
CleanChip Technologies Limited ("CleanChip")	Hong Kong, June 2017	Trading partner between ACM Shanghai and its customers	82.1 %	82.1 %
ACM Research Korea CO., LTD.	Korea, December 2017	Sales, marketing, R&D, production	82.1 %	82.1 %
ACM Research (Lingang), Inc. ("ACM Lingang") (1)	Mainland China, March 2019	Management of production activities	82.1 %	82.1 %
ACM Research (CA), Inc. ("ACM California")	USA, April 2019	Procurement for ACM Shanghai	82.1 %	82.1 %
ACM Research (Cayman), Inc.	Cayman Islands, April 2019	Administrative function (inactive)	100.0 %	100.0 %
ACM Research (Singapore) PTE. Ltd. ("ACM Singapore")	Singapore, August 2021	Sales, marketing, business development	100.0 %	100.0 %
ACM Research (Beijing), Inc. ("ACM Beijing")	Mainland China, February 2022	Sales, marketing, business development	82.1 %	82.1 %
Hanguk ACM CO., LTD	Korea, March 2022	Sales, services, business development	100.0 %	100.0 %
Yusheng Micro Semiconductor (Shanghai) Co., Ltd.	Mainland China, June 2023	Business development	82.1 %	82.1 %
ACM-Wooil Microelectronics (Shanghai Co., Ltd.) Mainland China, June 2023	Component development and production	59.4 %	59.4 %

(1) ACM Research (Lingang) Inc. is the English name referred to by its Chinese language name Shengwei Research (Shanghai), Inc., or ACM Shengwei in prior filings. ACM Research (Lingang), Inc. and Shengwei Research (Shanghai), Inc. refer to the same entity.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The Company's condensed consolidated financial statements include the accounts of ACM and its subsidiaries. ACM's subsidiaries are those entities in which ACM, directly or indirectly, controls a majority of the voting power. All significant intercompany transactions and balances have been eliminated upon consolidation.

The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission (the "SEC") for reporting on Form 10-Q. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the

Company for the year ended December 31, 2023 included in ACM's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

The accompanying condensed consolidated financial statements are unaudited. In the opinion of management, these unaudited condensed consolidated financial statements of the Company reflect all adjustments that are necessary for a fair presentation of the Company's financial position and results of operations. Such adjustments are of a normal recurring nature, unless otherwise noted. The balance sheet as of March 31, 2024 and the results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for any future period.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the balance sheet date and the reported revenues and expenses during the reported period in the condensed consolidated financial statements and accompanying notes. The Company's significant accounting estimates and assumptions include, but are not limited to, those used for revenue recognition and deferred revenue, the valuation and recognition of fair value of certain short-term investments and long-term investments, stock-based compensation arrangements, realization of deferred tax assets, assessment for impairment of long-lived assets and long-term investments, allowance for credit losses, inventory valuation, useful lives of property, plant and equipment and useful lives of intangible assets.

Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates and assumptions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, bank deposits that are unrestricted as to withdrawal and use, and highly liquid investments with an original maturity date of three months or less at the date of purchase. At times, cash deposits may exceed government-insured limits.

The following table presents cash and cash equivalents, according to jurisdiction as of March 31, 2024 and December 31, 2023:

	March 31, 2024	December 31, 2023	
United States	\$ 45,179	\$ 43,614	
Mainland China	101,590	70,418	
China Hong Kong	63,401	64,057	
Korea	1,068	3,934	
Singapore	67	67	
Total	\$ 211,305	\$ 182,090	

The amounts in mainland China do not include short-term and long-term time deposits which totaled \$76,205 and \$121,342 at March 31, 2024 and December 31, 2023, respectively.

Cash held in the U.S. exceeds the Federal Deposit Insurance Corporation insurance limits and is subject to risk of loss. No losses have been experienced to date.

Cash amounts held in mainland China are subject to a series of risk control regulatory standards from mainland China bank regulatory authorities. ACM's subsidiaries in mainland China are required to obtain approval from the State Administration of Foreign Exchange ("SAFE") to transfer funds into or out of mainland China. SAFE requires a valid agreement to approve the transfers, which are processed through a bank. Other than these mainland China foreign exchange restrictions, ACM's subsidiaries in mainland China are not subject to any restrictions and limitations on its ability to transfer funds to

ACM or among our other subsidiaries. However, cash held in mainland China does exceed applicable insurance limits and is subject to risk of loss, although no such losses have been experienced to date.

ACM California periodically procures goods and services on behalf of ACM Shanghai. For these transactions, ACM Shanghai makes cash payments to ACM California in accordance with applicable transfer pricing arrangements. For the three months ended March 31, 2024 and 2023, cash payments from ACM Shanghai to ACM California for the procurement of goods and services was \$4,648 and \$10,931, respectively. ACM California periodically borrows funds for working capital advances from its direct parent, CleanChip. ACM California repays or renews these intercompany loans in accordance with their terms.

For sales through CleanChip and ACM Research, a certain amount of sales or advanced payments from customers is repatriated back to ACM Shanghai in accordance with applicable transfer pricing arrangements in the ordinary course of business. ACM Research provides services to certain customers located in the U.S., Europe and other regions outside of mainland China to support the evaluation of first tools and provide support for tools under warranty on behalf of ACM Shanghai. For these transactions, ACM Shanghai makes cash payments to ACM Research in accordance with applicable transfer pricing arrangements.

Amounts held in Korea exceed the Korea Deposit Insurance Corporation insurance limits and is subject to risk of loss. No losses have been experienced to date. There is no additional restriction for the transfer of cash from bank accounts in the U.S., Korea, Singapore and Hong Kong.

For the three months ended March 31, 2024 and 2023, with the exception of sales and services-related transfer-pricing payments in the ordinary course of business, no transfers, or distributions have been made between ACM Research and its subsidiaries, including ACM Shanghai, or to holders of ACM Research Class A common stock.

Time Deposits

Time deposits are deposited with banks in mainland China with fixed terms and interest rates which cannot be withdrawn before maturity, and are presented as short-term deposits and long-term deposits in the condensed consolidated financial statements based on their expected time of collection. They are also subject to the risk control regulatory standards described above upon maturity.

1	1
1	L

At March 31, 2024 and December 31, 2023, time deposits consisted of the following:

	March 31, 2024	December 31, 2023
Deposit in China Merchant Bank which matured on January 29, 2024 with an annual interest rate of 2.85%	\$ — \$	5 29,797
Deposit in Bank of Ningbo which matured on February 17, 2024 with an annual interest rate of 2.85%	\$ — \$	5 44,630
Deposit in Shanghai Pudong Development Bank which matures on October 20, 2025 with an annual interest rate of 3.10%	\$ 7,361 \$	5 7,322
Deposit in Shanghai Pudong Development Bank which matures on November 14, 2025 with an annual interest rate of 3.10%	\$ 4,407 \$	5 7,307
Deposit in Shanghai Pudong Development Bank which matures on December 8, 2025 with an annual interest rate of 3.10%	\$ — \$	4,376
Deposit in Shanghai Pudong Development Bank which matures on December 15, 2025 with an annual interest rate of 3.10%	\$ 1,465 \$	4,373
Deposit in Shanghai Pudong Development Bank which matures on December 30, 2025 with an annual interest rate of 3.10%	\$ — \$	5 2,912
Deposit in China Industrial Bank which matures on January 3, 2026 with an annual interest rate of 3.15%	\$ 14,608 \$	5 14,528
Deposit in China Everbright Bank which matures on December 5, 2024 with an annual interest rate of 5.38%	\$ — \$	3,079
Deposit in China Everbright Bank which matures on May 22, 2024 with an annual interest rate of 5.28%	\$ 3,057 \$	3,018
Deposit in China Everbright Bank which matured on April 5, 2024 with an annual interest rate of 5.33%	\$ 3,037 \$	S —
Deposit in China Merchant Bank, Lujiazui Branch which matures on May 27, 2024 with an annual interest rate of 1.85%	\$ 14,090 \$	S —
Deposit in China Merchant Bank, Huaihai Branch which matures on May 27, 2024 with an annual interest rate of 1.85%	\$ 14,090 \$	S —
Deposit in Bank of Ningbo which matures on September 11, 2024 with an annual interest rate of 1.50%	\$ 14,090 \$	S
	\$ 76,205 \$	5 121,342

For the three months ended March 31, 2024 and 2023, interest income related to time deposits was \$624 and \$975, respectively.

Financial Instruments

The Company periodically invests in equity securities, and maintains an investment portfolio of various holdings, types, and maturities. For equity investments that do not have a readily determinable fair value, the Company classified them as long-term investments, and records them using either: 1) the measurement alternative which measures the equity investments at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes; or 2) the equity method whereby the Company recognizes its proportional share of the income or loss from the equity method investment. The equity method is utilized when the equity investments are common stock or in substance common stock, and the Company does not have the ability to control the investee but is deemed to have the ability to exercise significant influence over the investee's operating or financial policies. For equity investments that have a readily determinable fair value, the Company classified them as short-term investments, and records them at fair market value on a recurring basis based upon quoted market prices. Realized and unrealized gains and losses resulting from application of the measurement alternative, the impact of the application of the equity method to the Company's equity investments, and recognition of

changes in fair market value, as applicable, are recognized as non-operating income (expenses), net in the condensed consolidated statements of comprehensive income.

The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.

A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The level of an asset or liability in the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities with sufficient volume and frequency of transactions.

Level 2: Valuations based on observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active for identical assets or liabilities, or model-derived valuations techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Valuations based on unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities and based on non-binding, broker-provided price quotes and may not have been corroborated by observable market data.

The Company's primary financial instruments include its cash, cash equivalents, short term and long term deposits, restricted cash, short-term and long-term investments, other receivables, accounts receivable, accounts payable, and short-term and long-term borrowings. The estimated fair value of cash and cash equivalents, short-term time deposits, accounts receivable, other receivables, accounts payable, and short-term borrowings approximates their carrying value due to the short period of time to their maturities.

All transfers between fair value hierarchy levels are recognized by the Company at the end of each reporting period. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value

measurement in its entirety, requires judgment and considers factors specific to the investment. The inputs or methodology

used for valuing financial instruments are not necessarily an indication of the risks associated with investment in those instruments.

Assets and liabilities measured at fair value on a recurring basis:

ACM RESEARCH, INC. Notes to the Condensed Consolidated Financial Statements

(In thousands, except share, percentage and per share data)

	Marke	Prices in Active ts for Identical ities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
As of March 31, 2024:					
Assets					
Cash and cash equivalents	\$	36,509	\$ —	\$ _ \$	36,509
Short-term investments		18,648	—	—	18,648
	\$	55,157	\$ —	\$ _ \$	55,157
As of December 31, 2023:					
Assets					
Cash and cash equivalents	\$	37,518	\$ —	\$ _ \$	37,518
Short-term investments		21,312	—	—	21,312
	\$	58,830	\$ —	\$ - \$	58,830

Assets and liabilities measured at fair value on a non-recurring basis:

	Quoted Prices in Ac Markets for Identi Liabilities (Level	cal	Obser	ficant Other vable Inputs Level 2)	Significant Unobservable Inputs (Level 3)		Total
As of December 31, 2023:							
Assets							
Investments accounted for using measurement alternative	\$	_	\$	_	\$	10,378	\$ 10,378
	\$		\$	_	\$	10,378	\$ 10,378

The Company did not have any assets and liabilities measured at fair value on a non-recurring basis as of March 31, 2024, and the Company did not recognize any unrealized gains (upward adjustments) or unrealized losses (downward adjustments) resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer for its long-term investments accounted for using measurement alternatives during the three months ended March 31, 2024 and 2023.

Refer to Note 12 for fair value information related to the Company's outstanding long-term borrowings as of March 31, 2024 and December 31, 2023.

Basic and Diluted Net Income per Share of Common Stock

Basic and diluted net income per share of common stock are calculated as follows:

	Three Months Ended March 31,			arch 31,
		2024		2023
Numerator:				
Net income	\$	22,092	\$	8,963
Less: Net income attributable to non-controlling interests		4,659		1,818
Net income available to common stockholders, basic	\$	17,433	\$	7,145
Less: Dilutive effect arising from stock-based awards by ACM Shanghai		354		93
Net income available to common stockholders, diluted	\$	17,079	\$	7,052
Weighted average shares outstanding, basic		61,367,184		59,736,764
Effect of dilutive securities		4,875,137		5,322,013
Weighted average shares outstanding, diluted		66,242,321		65,058,777
Net income per share of common stock:				
Basic	\$	0.28	\$	0.12
Diluted	\$	0.26	\$	0.11

Basic and diluted net income per share of common stock is presented using the two-class method, which allocates undistributed earnings to common stock and any participating securities according to dividend rights and participation rights on a proportionate basis. Under the two-class method, basic net income per share of common stock is computed by dividing the sum of distributed and undistributed earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. ACM Research did not have any participating securities outstanding during the three months ended March 31, 2024 and 2023.

ACM Research has been authorized to issue Class A and Class B common stock since redomesticating in Delaware in November 2016. The two classes of common stock are substantially identical in all material respects, except for voting rights. Since ACM Research did not declare any cash dividends during the three months ended March 31, 2024 or 2023, the net income per share of common stock attributable to each class is the same under the "two-class" method. As such, the two classes of common stock have been presented on a combined basis in the condensed consolidated statements of comprehensive income and in the above computation of net income per share of common stock.

Diluted net income per share of common stock reflects the potential dilution from securities, such as stock options that could share in ACM Research's earnings. Certain potential dilutive securities were excluded from the net income per share calculation because the impact would be anti-dilutive. The number of potentially dilutive shares that were not included in the calculation of diluted net income per share in the periods presented where their inclusion would be anti-dilutive were 728,575 and 1,967,685 stock options for the three months ended March 31, 2024 and 2023, respectively.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, time deposits, and accounts receivable. The Company deposits and invests its cash and cash equivalents and time deposits with financial institutions that management believes are creditworthy.

The Company is potentially subject to concentrations of credit risks in its revenue and accounts receivable. For the three months ended March 31, 2024 and 2023, two customers accounted for 55.9% and four customers accounted for 59.7% of revenue, respectively.

As of March 31, 2024 and December 31, 2023, four customers accounted for 56.2% and four customers accounted for 59.1%, respectively, of the Company's accounts receivables. The Company believes that the receivable balances from these largest customers do not represent a significant credit risk based on past collection experience.

Recently issued accounting pronouncements not yet adopted

In November 2023, the FASB issued ASU No. 2023-07, *Improvements to Reportable Segment Disclosures*. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. The Company is currently evaluating the provisions of this ASU and expect to adopt it for the year ending December 31, 2024.

In December 2023, the FASB issued ASU No. 2023-09, *Improvements to Income Tax Disclosures* (Topic 740). The ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Retrospective application is permitted. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the provisions of this ASU.

NOTE 3 – REVENUE FROM CONTRACTS WITH CUSTOMERS

The Company assesses revenues based upon the nature or type of goods or services it provides and the geographic location of the customer facility. The following tables present disaggregated revenue information:

	Three Months Ended March 31,					
		2024		2023		
Single Wafer Cleaning, Tahoe and Semi-Critical Cleaning Equipment	\$	109,470	\$	36,614		
ECP (front-end and packaging), Furnace and Other Technologies		25,800		26,598		
Advanced Packaging (excluding ECP), Services & Spares		16,921		11,044		
Total Revenue by Product Category	\$	152,191	\$	74,256		

		Three Months Ended March 31,				
	2024			2023		
Mainland China	\$	152,135	\$	72,458		
Other regions		56		1,798		
	\$	152,191	\$	74,256		

Below are the accounts receivables and contract liabilities balances as of:

	March 31, 2024	December 31, 2023
Accounts receivable	296,371	283,186
Advances from customers	182,547	181,368
Deferred revenue	4,405	3,687

During the three months ended March 31, 2024, advances from customers increased by \$1.2 million, due to an increase of payments made by customers for first tools under evaluation, offset by a decrease in customer pre-payments for tools prior to delivery.

Below are revenues recognized from amounts included in contract liabilities at the beginning of the year:

	Three Months Ended March 31,				
	2024	2023			
Revenue recognized from amounts included in contract liabilities at the	\$ 29,188	\$ 15,212			
beginning of the year					

NOTE 4 – ACCOUNTS RECEIVABLE

At March 31, 2024 and December 31, 2023, accounts receivable consisted of the following:

	March 31, 2024		December 31, 2023
Accounts receivable	\$ 302,37	2 \$	288,016
Less: Allowance for credit losses	(6,00	1)	(4,830)
	\$ 296,37	1 \$	283,186

The \$13.2 million increase in accounts receivable for the first three months of 2024 corresponds to a \$77.9 million increase in revenue for the same period. The movement of the allowance for credit losses for the three months ended March 31, 2024 is as follows:

	March 31, 2024
Allowance for credit losses, before tax, as of January 1	\$ (4,830)
Provision for credit losses	(1,171)
Allowance for credit losses, before tax, as of March 31	\$ (6,001)

The Company assesses collectability by reviewing accounts receivable on a general basis where similar characteristics exist and on an individual basis when the Company identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status, the age of the accounts receivable balances, credit quality of the Company's customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect the Company's ability to collect from customers.

NOTE 5 – INVENTORIES

At March 31, 2024 and December 31, 2023, inventories consisted of the following:

	N	farch 31, 2024	De	December 31, 2023	
Raw materials	\$	256,332	\$	235,062	
Work-in-process		61,871		81,438	
Finished goods		262,937		228,895	
Total inventory	\$	581,140	\$	545,395	

At March 31, 2024 and December 31, 2023, the value of finished goods inventory of which were first-tools at customer physical locations for which customers were contractually obligated to take ownership upon acceptance totaled \$163,484 and \$123,390, respectively.

The \$21,270 increase in raw materials at March 31, 2024 compared to December 31, 2023 was due to additional purchase of supplies to support a higher level of expected total shipments for the next several quarters, and to reduce the risk of supply chain delays to meet anticipated customer demand for the Company's products.

The \$34,042 increase in finished goods inventory at March 31, 2024 compared to December 31, 2023 reflects a higher value of first-tools under evaluation by existing or prospective customers, due to shipments made, net of customer acceptances during the period.

The Company's products each require a certain degree of customization, and the substantial majority of the work-in-process inventory and finished goods inventory is built to meet a specific customer order for a repeat shipment or a first tool shipment. At the end of each period, the Company assesses the status of each item in work-in-process and finished goods inventory. The Company recognizes a loss or impairment if in management's judgement the inventory cannot be sold or used for production, if it has been damaged or should be considered as obsolete, or if the net realizable value is lower than the cost.

At the end of each period, the Company also assesses the status of its raw materials. The Company recognizes a loss or impairment for any raw materials aged more than three years. The three-year aging is based on the Company's assessment of technology change, its requirement to maintain stock for warranty coverage, and other factors.

During the three months ended March 31, 2024 and 2023, provision for inventory of \$1,025 and \$306 were recognized in cost of revenue, respectively. Write-downs were due to an internal assessment that certain inventory could not be sold or used for production due to damage or obsolescence.

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT, NET

At March 31, 2024 and December 31, 2023, property, plant and equipment consisted of the following:

	March 31, 2024	December 31, 2023
Buildings and plants	\$ 82,933	\$ 83,109
Manufacturing equipment	16,702	16,556
Office equipment	5,061	4,953
Transportation equipment	402	404
Leasehold improvement	7,961	7,889
Total cost	113,059	112,911
Less: Total accumulated depreciation and amortization	(19,531)) (17,503)
Construction in progress	125,294	106,440
Total property, plant and equipment, net	\$ 218,822	\$ 201,848

Depreciation expense for the three months ended March 31, 2024 and 2023 was \$2,475 and \$1,714, respectively. Buildings and plants represent Lingang housing property owned by ACM Liangang at a value of RMB 249,746 (\$35,189), and facilities for the new headquarters of ACM Shanghai ("Zhangjiang New Building") at a value of RMB 338,848 (\$47,744), as of March 31, 2024. The Lingang housing property is pledged as security for loans from China Merchants Bank (Note 12).

Construction in progress primarily reflects costs incurred related to the construction of ACM Shanghai's Lingang development and production center, and is scheduled to begin production in the second half of 2024.

NOTE 7 – LAND USE RIGHT, NET

A summary of land use right is as follows:

	Μ	arch 31, 2024	D	ecember 31, 2023
Land use right purchase amount	\$	8,977	\$	8,996
Less: accumulated amortization		(672)		(629)
Land use right, net	\$	8,305	\$	8,367

The amortization for the three months ended March 31, 2024 and 2023 was \$43 and \$50, respectively.

The annual amortization of land use right is as follows:

Year ending December 31,	
remainder of 2024	\$ 135
2025	180
2026	180
2027	180
2028	180
2029 and thereafter	7,450
Total	\$ 8,305

NOTE 8 – OTHER LONG-TERM ASSETS

At March 31, 2024 and December 31, 2023, other long-term assets consisted of the following:

	March 31, 2024	December 31, 2023
Prepayments for property, plant and equipment	\$ 7,690	\$ 3,380
Lease deposits	867	834
Security deposit for land use right	695	696
Others	1,219	1,140
Total other long-term assets	\$ 10,471	\$ 6,050

NOTE 9 – SHORT-TERM BORROWINGS

At March 31, 2024 and December 31, 2023, short-term borrowings consisted of the following:

	Marc 202	,	December 31, 2023
Line of credit up to RMB 150,000 from China Everbright Bank,			
1)due on August 29, 2024 with an annual interest rate of 3.00%.		2,459	2,463
Line of credit up to RMB 40,000 from Bank of China,			
1)due on September 7, 2024 with an annual interest rate of 2.87%.		5,640	5,648
Line of credit up to RMB 200,000 from China Merchants Bank,			
1)due on August 7, 2024 with an annual interest rate of 3.00%.		1,269	1,271
2) due on August 8, 2024 with an annual interest rate of 3.00%.		1,269	1,271
3)due on August 9, 2024 with an annual interest rate of 3.00%.		1,269	1,271
4) due on August 14, 2024 with an annual interest rate of 3.00%.		1,269	1,271
5)due on August 17, 2024 with an annual interest rate of 3.00%.		1,269	1,271
6)due on August 20, 2024 with an annual interest rate of 3.00%.		1,269	1,271
7)due on August 21, 2024 with an annual interest rate of 3.00%.		1,269	1,271
8) due on August 22, 2024 with an annual interest rate of 3.00%.		1,269	1,271
9) due on August 24, 2024 with an annual interest rate of 3.00%.		1,269	1,271
10)due on August 27, 2024 with an annual interest rate of 3.00%.		1,269	1,271
11)due on August 29, 2024 with an annual interest rate of 3.00%.		1,269	1,271
12)due on August 30, 2024 with an annual interest rate of 3.00%.		1,269	1,271
13)due on September 3, 2024 with an annual interest rate of 3.00%.		1,269	1,271
14)due on September 5, 2024 with an annual interest rate of 3.00%.		1,269	1,270
15)due on September 6, 2024 with an annual interest rate of 3.00%.		1,269	1,270
16)due on September 10, 2024 with an annual interest rate of 3.00%.		1,269	1,270
17)due on September 12, 2024 with an annual interest rate of 3.00%.		1,269	1,270
18) due on February 27, 2025 with an annual interest rate of 2.60%.		1,340	_
19) due on February 28, 2025 with an annual interest rate of 2.60%.		1,340	_
20)due on March 1, 2025 with an annual interest rate of 2.60%.		1,340	—
21)due on March 5, 2025 with an annual interest rate of 2.60%.		1,340	—
22) due on March 8, 2025 with an annual interest rate of 2.60%.		1,270	—
Line of credit up to RMB 120,000 from Bank of China,			
1) due on March 20, 2025 with an annual interest rate of 2.75%.		16,921	—
Line of credit up to KRW 500,000 from Industrial Bank of Korea,			
1)due on July 12, 2024 with an annual interest rate of 6.03%.		—	77
Line of credit up to KRW 2,000,000 from Industrial Bank of Korea,			
1)due on December 15, 2024 with an annual interest rate of 4.27%.		1,483	1,544
Total	\$	54,706 \$	31,335

For the three months ended March 31, 2024 and 2023, interest expense related to short-term borrowings amounted to \$213 and \$490, respectively.

NOTE 10 - OTHER PAYABLES AND ACCRUED EXPENSES

At March 31, 2024 and December 31, 2023, other payables and accrued expenses consisted of the following:

	March 31, 2024	December 31, 2023
Accrued commissions	\$ 15,932 \$	15,572
Accrued warranty	11,339	9,834
Accrued payroll	16,550	14,840
Accrued professional fees	113	696
Accrued machine testing fees	1,863	1,762
Accrued machine sales fees	4,942	6,010
Accrued Lingang construction fees	33,546	33,729
Others	22,813	20,508
Total	\$ 107,098 \$	102,951

NOTE 11 – LEASES

The Company leases space under non-cancelable operating leases for several offices and manufacturing locations. These leases do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions.

Most leases include one or more options to renew. The Company regularly evaluates the renewal options, and when they are reasonably certain of exercise, the Company includes the renewal period in its lease term.

The components of lease expense were as follows:

	Tł	Three Months Ended March 31,			
		2024	2023		
Operating lease cost	\$	973 \$	488		
Short-term lease cost		321	282		
Total lease cost	\$	1,294 \$	770		

Supplemental cash flow information related to operating leases was as follows:

	Three Months Ended March 31,		
		2024	2023
Operating cash outflow from operating leases	\$	973 9	488
Operating lease right-of-use assets obtained in exchange for new operating lease liabilities	\$	80 5	6,592



As of March 31, 2024, maturities of outstanding lease liabilities for all operating leases were as follows:

	Dec	cember 31,
remainder of 2024	\$	2,370
2025		1,800
2026		1,215
2027		1,148
2028 and thereafter		595
Total lease payments	\$	7,128
Less: Interest		(630)
Present value of lease liabilities	\$	6,498

The weighted average remaining lease terms and discount rates for all operating leases were as follows:

	March 31, 2024	December 31, 2023
Remaining lease term and discount rate:		
Weighted average remaining lease term (years)	3.37	3.44
Weighted average discount rate	3.87 %	3.91 %

NOTE 12 – LONG-TERM BORROWINGS

At March 31, 2024 and December 31, 2023, long-term borrowings consisted of the following:

	March 31, 2024	December 31, 2023
Loan from China Merchants Bank	\$ 12,919 \$	13,362
Loans from Bank of China	4,759	5,013
Loan from Bank of Shanghai	14,101	14,120
Loan from China CITIC Bank	28,178	28,240
Less: Current portion	(6,549)	(6,783)
Total	\$ 53,408 \$	53,952

The loan from China Merchants Bank is for the purpose of purchasing housing property in Lingang, Shanghai. The loan is repayable in 120 total installments with the last installment due in November 2030, with an annual interest rate of 3.95%. The loan is pledged by the property of ACM Lingang and guaranteed by ACM Shanghai.

Two loans from Bank of China are for the purpose of funding ACM Shanghai project expenditures. The loans bear interest at an annual rate of 2.6% and are repayable in 6 installments, with the last installments due in June 2024 and September 2024, respectively.

The loan from Bank of Shanghai is for the purpose of funding ACM Shanghai project expenditures. The loan bears interest at an annual rate of 2.85%, and will be fully repaid in April 2025.

The first loan from China CITIC Bank is for the purpose of funding ACM Shanghai project expenditures. The loan bears interest at an annual rate of 3.1% and is repayable in 4 installments, with the last installment due in August 2025.

The second loan from China CITIC bank is for the purpose of funding ACM's general corporate expenses and working capital. The loan bears interest at an annual rate of 4.50% payable quarterly, and the principal amount is repayable in 4

installments, with the last installment due in December 2025.

As of March 31, 2024 and December 31, 2023, the total carrying amount of long-term loans was \$59,957 and \$60,735, compared with an estimated fair value of \$56,409 and \$56,462, respectively. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level 2 fair value measurement). Refer to Note 2 for an explanation of the fair value hierarchy structure.

Scheduled principal payments for the outstanding long-term loan, including the current portion, as of March 31, 2024 are as follows:

	(100
remainder of 2024 \$	6,120
2025	43,993
2026	1,851
2027	1,925
2028	2,003
Thereafter	4,065
\$	59,957

For the three months ended March 31, 2024 and 2023, respectively, interest related to long-term borrowings of \$570 and \$189 was incurred, and all of them were charged to interest expenses.

NOTE 13 – OTHER LONG-TERM LIABILITIES

Other long-term liabilities represent government subsidies received from mainland China governmental authorities for development and commercialization of certain technology but not yet recognized. At March 31, 2024 and December 31, 2023, other long-term liabilities consisted of the following uncarned government subsidies:

	Marcl	n 31, 2024	December 31, 2023
Subsidies to Stress Free Polishing project, commenced in 2008 and 2017	\$	189 \$	475
Subsidies to other cleaning tools, commenced in 2020		647	632
Subsidies to SW Lingang R&D development in 2021		3,454	3,467
Other		1,179	1,299
Total	\$	5,469 \$	5,873

NOTE 14 – LONG-TERM INVESTMENTS

On January 12, 2024, ACM Shanghai entered into an investment agreement with Company C to invest RMB 12,500 (\$1,760), which represented 0.3% of the Company C's total equity interest. Since there is no readily determinable fair value, the Company measures the investments at measurement alternative.

On January 19, 2024, ACM Shanghai entered into a limited partnership agreement with Company D to invest RMB 30,000 (\$4,230), which represented 16.7% of the partnership's total equity interest. The investment in the limited partnership with Company D is accounted for under the equity method in accordance with ASC323-30-S99-1.

Equity investee:	Initial investment dates	Investment entity	Percent ownership by ACM and subsidiaries	1
Ninebell Co., Ltd. ("Ninebell")	September 2017	ACM	20.0%	\$ 1,200
Shengyi Semiconductor Technology Co., Ltd. ("Shengyi")	June 2019	ACM Shanghai	14.0%	\$ 109
Hefei Shixi Chanheng Integrated Circuit Industry Venture Capital FundPartnership (LP) ("Hefei Shixi")	September 2019	ACM Shanghai	10.0%	RMB 30,000 (\$4,200)
Wooil Flucon Co. ("Wooil")	August 2022	ACM Singapore	20.0%	\$ 1,000
Company D	February 2024	ACM Shanghai	16.7%	RMB 30,000 (\$4,230)
Investments accounted for using measurement alternative:	-			
Waferworks (Shanghai) Co., Ltd. ("Waferworks")	October 2021	ACM Shanghai	0.3%	\$ 1,568
Company A	September 2023	ACM Shanghai	4.4%	RMB 30,000 (\$4,200)
Shengyi	September 2023	ACM Shanghai	1.0%	RMB 6,100 (\$860)
Company B	November 2023	ACM Shanghai	1.4%	RMB 6,600 (\$930)
Company C	February 2024	ACM Shanghai	5.0%	RMB 12,500 (\$1,760)

Equity investee:	March 31, 2024	December 31, 2023
Ninebell	\$ 5,481 \$	5,632
Wooil	989	1,003
Shengyi	1,999	1,693
Hefei Shixi	7,888	9,174
Company D	4,227	—
Subtotal	 20,584	17,502
Investments accounted for using measurement alternative:		
Waferworks	—	1,412
Shengyi	856	857
Company A	4,227	4,236
Company B	930	932
Company C	1,761	_
Other	2,935	2,941
Total	 31,293	27,880

For the three months ended March 31, 2024 and 2023, the Company's share of equity investees' net loss was \$520 and \$32, respectively, which amounts were included in loss from equity method investments in the accompanying condensed consolidated statements of comprehensive income. For the three months ended March 31, 2024 and 2023, the Company received \$600 and \$0 dividends from equity investee.

NOTE 15 – SHORT-TERM INVESTMENTS

Pursuant to an Agreement entered into on September 19, 2022 (the "Agreement"), ACM Shanghai became a limited partner of the Nuode Asset Fund Pujiang No. 783 Single Asset Management Plan ("Nuode Asset Fund"), a Chinese limited partnership formed by Nuode Asset Management Co., Ltd, a financial services firm based in Shanghai, China. Nuode Asset Fund was formed to establish a special fund with the purpose to participate in certain technology related investments in mainland China. Subsequent to the future purchase, any investment will be held by Nuode Asset Fund and restricted for a minimum period of nine months. The limited partners of the Nuode Asset Fund contributed a total RMB 160 million (\$22,160) to the fund, of which ACM Shanghai contributed RMB 30 million (\$4,196), or 18.75% of the contribution on September 27, 2022.

In December 2022, the Nuode Asset Fund purchased shares in the secondary stock offering of a publicly traded mainland China-stock listing. The number of shares owned by Nuode Asset Fund was apportioned to all of the limited partners in proportion to their respective capital contributions which is 18.75% in the case of ACM Shanghai. The investments were fully disposed in the three months ended March 31, 2024 and the Company has not received the proceeds as of March 31, 2024 with a receivable of RMB 22,478 (\$3,167) was recorded.

Pursuant to a Share Purchase Agreement dated June 2023, ACM Shanghai acquired shares of Huahong Semiconductor Limited ("Huahong") in July 2023 with amount of RMB 100 million (\$13,930). The shares held by ACM Shanghai are restricted for sale for a minimum period of twelve months. Huahong completed its STAR IPO in August 2023.

Pursuant to a Share Purchase Agreement dated August 2023, ACM Shanghai acquired shares of Zhongjuxin Limited Company ("Zhongjuxin") in September 2023 with amount of RMB 30 million (\$4,179). The shares held by ACM Shanghai are restricted for sale for a minimum period of twelve months. Zhongjuxin completed its STAR IPO in September 2023.

Pursuant to a Share Purchase Agreement dated January 2024, ACM Shanghai acquired shares of Shanghai Syncrystalline Silicon Materials Co., Ltd. ("Syncrystalline") in February 2024 with amount of RMB 10,000 (\$1,409). The shares held by ACM Shanghai are restricted for sale for a minimum period of twelve months. Syncrystalline completed its STAR IPO in February 2024. As of March 31, 2024, the Company's total investment costs in Syncrystalline were RMB 20,000(\$2,818), including RMB 10,000 (\$1,409) invested by ACM Shanghai in 2021 and RMB 10,000 (\$1,409) invested by ACM Shanghai in February 2024.

At March 31, 2024 and December 31, 2023, the components of short-term investments were as follows:

	N	1arch 31, 2024	December 31, 2023
Short-term investments listed in Shanghai Stock Exchange			
Cost	\$	21,135 \$	20,155
Market value		18,648	21,312

For the three months ended March 31, 2024 and 2023, the net gains (losses) recognized on equity securities were as follows:

	Three Months Ended March 31,		
	2024		2023
Unrealized losses recognized during the reporting period on equity securities still held at March 31	\$	(2,595) \$	(654)
Net gains recognized during the period on equity securities sold during the period	\$	273 \$	3,994
Total net gains (losses) recognized at March 31 on equity securities	\$	(2,322) \$	3,340

For the three months ended March 31, 2024, the Company recognized a receivable of RMB 22,478 (\$3,167) from the sales of short-term investments, including a realized gain of \$273.

For the three months ended March 31, 2023, the Company received \$11,072 in proceeds from the sale of short-term investments, including a realized gain of \$3,994.

NOTE 16 - RELATED PARTY BALANCES AND TRANSACTIONS

Ninebell

Ninebell is an equity investee of ACM (Note 14) and is the Company's principal supplier of robotic delivery system subassemblies used in our single-wafer cleaning equipment. The Company purchases equipment from Ninebell for production in the ordinary course of business. The Company pays for a portion of the equipment in advance and is obligated for the remaining amounts upon receipt of the product.

Shengyi

Shengyi is an equity investee of ACM Shanghai (Note 14) and is one of the Company's component suppliers in mainland China. The Company purchases components from Shengyi for production in the ordinary course of business. The Company incurs a service fee related to installation and hook-up fees which is recorded within cost of revenue on the Company's condensed consolidated statements of comprehensive income. The Company pays for a portion of the raw materials in advance and is obligated for the remaining amounts upon receipt of the product.

All related party outstanding balances are short-term in nature and are expected to be settled in cash.

The following tables reflect related party transactions in our condensed consolidated financial statements:

Advances to related party	March 31, 2024	December 31, 2023
Ninebell	\$ 1,338 \$	2,432
Accounts payable	March 31, 2024	December 31, 2023
Ninebell	\$ 12,571 \$	7,624
Shengyi	3,672	3,783
Total	\$ 16,243 \$	11,407

Shengyi

ACM RESEARCH, INC. Notes to the Condensed Consolidated Financial Statements (In thousands, except share, percentage and per share data)

	TI	Three Months Ended March 31,					
Purchase of materials		2024	2023				
Ninebell	\$	14,152 \$	16,397				
Shengyi		992	1,973				
Total	\$	15,144 \$	18,370				
	Thre	e Months Ended M	arch 31,				
Service fee charged by	20	024	2023				

\$

NOTE 17 – COMMON STOCK

ACM is authorized to issue 150,000,000 shares of Class A common stock and 5,307,816 shares of Class B common stock, each with a par value of \$0.0001. Each share of Class A common stock is entitled to one vote, and each share of Class B common stock is entitled to twenty votes and is convertible at any time into one share of Class A common stock. Shares of Class A common stock and Class B common stock are treated equally, identically and ratably with respect to any dividends declared by the Board of Directors of ACM unless such Board of Directors declares different dividends to the Class A common stock and Class B common stock, which is subject to approval from a majority of common stockholders.

73 \$

278

During the three months ended March 31, 2024, ACM issued 950,605 shares of Class A common stock upon option exercises by employees and non-employees.

During the three months ended March 31, 2023, ACM issued 163,069 shares of Class A common stock upon option exercises by employees and non-employees.

At March 31, 2024 and December 31, 2023, the number of shares of Class A common stock issued and outstanding was 56,986,777 and 56,036,172, respectively.

At March 31, 2024 and December 31, 2023, the number of shares of Class B common stock issued and outstanding was 5,021,811 and 5,021,811, respectively.

NOTE 18 - STOCK-BASED COMPENSATION

ACM's stock-based compensation consists of employee and non-employee awards issued under its 1998 Stock Option Plan and its 2016 Omnibus Incentive Plan. The vesting condition may consist of a service period condition determined by the Board of Directors for a grant or certain performance conditions determined by the Board of Directors for a grant. The fair value of the stock options granted with a service period based condition and/or performance condition is estimated at the date of grant using the Black-Scholes option pricing model. The fair value of the stock options granted with a market based condition is estimated at the date of grant using the Monte Carlo simulation model.

Employee Awards

The following table summarizes the Company's employee share option activities during the three months ended March 31, 2024:

	Number of Option Shares	Weighted Average Grant Date Fair Value	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term
Outstanding at December 31, 2023	9,998,637 \$	5.15	\$ 9.59	6.17 years
Granted	3,000	23.95	31.92	
Exercised	(851,954)	2.7	5.74	
Forfeited/cancelled	(24,330)	11.14	23.08	
Outstanding at March 31, 2024	9,125,353 §	5.37	\$ 9.79	6.07 years
Vested and exercisable at March 31, 2024	5,278,784			

As of March 31, 2024 and December 31, 2023, \$24,670 and \$27,152, respectively, of total unrecognized employee stock-based compensation expense, net of estimated forfeitures, related to employee stock-based awards for ACM were expected to be recognized over a weighted-average period of 3.8 years and 4.0 years, respectively. Total recognized compensation cost may be adjusted for future changes in estimated forfeitures.

The aggregate intrinsic value of options exercised in the three months ended March 31, 2024 was \$21,865. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2024 were \$178,674 and \$117,476, respectively.

The fair value of options granted to employees is estimated on the grant date using the Black-Scholes valuation with following assumptions:

	Three Months Ended March 31, 2024
Fair value of common share(1)	31.92
Expected term in years(2)	6.25
Volatility(3)	85.48%
Risk-free interest rate(4)	4.23%
Expected dividend (5)	—%

(1) Fair value of Class A common stock value was closing market price of the Class A common stock on the grant date.

(2) Expected term of share options is based on the average of the vesting period and the contractual term for each grant.

(3) Volatility is calculated based on the historical volatility of ACM in the period equal to the expected term of each grant.

(4) Risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the share options in effect at the time of grant.

(5) Expected dividend is assumed to be 0% as ACM has no history or expectation of paying a dividend on its common stock.

Non-employee Awards

The following table summarizes the Company's non-employee share option activities during the three months ended March 31, 2024:

	Number of Option Shares	Weighted Average Grant Date Fair Value	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term
Outstanding at December 31, 2023	1,170,795 \$	6 0.42 \$	1.31	2.66 years
Exercised	(98,651)	0.22	0.50	
Forfeited/cancelled	(1,903)	0.22	0.50	
Outstanding at March 31, 2024	1,070,241 5	6 0.44 \$	1.39	2.51 years
Vested and exercisable at March 31, 2024	1,070,241			

As of March 31, 2024 and December 31, 2023, \$0 and \$9, respectively, of total unrecognized non-employee stock-based compensation expense, net of estimated forfeitures, related to stock-based awards were expected to be recognized over a weighted-average period of 0 years and 0.2 years, respectively. Total recognized compensation cost may be adjusted for future changes in estimated forfeitures.

The aggregate intrinsic value of options exercised in the three months ended March 31, 2024 was \$2,756. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2024 was \$29,702.

ACM Shanghai 2019 Option Grants

In January 2020, ACM Shanghai adopted a 2019 Stock Option Incentive Plan (the "2019 Subsidiary Stock Option Plan") that provides for, among other incentives, the granting to officers, directors, and employees of options to purchase shares of ACM Shanghai's common stock.

The following table summarizes the stock option activities of the ACM Shanghai 2019 Subsidiary Stock Option Plan during the three months ended March 31, 2024:

	Number of Option Shares in ACM Shanghai	Weighted Average Grant Date Fair Value	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term
Outstanding at December 31, 2023	3,134,883 \$	0.24 \$	1.85	0.85 years
Forfeited/cancelled	(92,308) \$	0.24 \$	1.85	
Outstanding at March 31, 2024	3,042,575	0.24 \$	1.85	0.65 years
Vested and exercisable at March 31, 2024	3,042,575			

The aggregate intrinsic value of options exercised in the three months ended March 31, 2024 was \$0. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2024 was \$31,616.

ACM Shanghai 2023 Option Grants

In June 2023, ACM Shanghai adopted a 2023 Stock Option Incentive Plan (the "2023 Subsidiary Stock Option Plan") that provides for, among other incentives, the granting to officers, directors, and employees of options to purchase shares of ACM Shanghai's common stock. The vesting conditions consist of service periods conditions and performance conditions

related to certain sales and research and development progress targets determined by the Board of Directors of ACM Shanghai.

The following table summarizes the ACM Shanghai 2023 Subsidiary Stock Option Plan's stock option activities during the three months ended March 31, 2024:

	Number of Option Shares in ACM Shanghai	Weighted verage Grant ate Fair Value	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term
Outstanding at December 31, 2023	10,575,500	\$ 9.49	\$ 7.06	3.09 years
Forfeited/cancelled	(84,000)	\$ 9.49	\$ 7.06	
Outstanding at March 31, 2024	10,491,500	\$ 9.12	\$ 7.01	2.84 years
Martin Landa and State 11 and March 21, 2024				

Vested and exercisable at March 31, 2024

During the three months ended March 31, 2024, ACM Shanghai did not grant any options from the 2023 Subsidiary Stock Option Plan. As of March 31, 2024 and December 31, 2023, \$65,682 and \$79,882, respectively, of total unrecognized non-employee stock-based compensation expense, net of estimated forfeitures, related to ACM Shanghai stock-based awards were expected to be recognized over a weighted-average period of 1.8 years and 2.1 years, respectively. Total recognized compensation cost may be adjusted for future changes in estimated forfeitures.

The aggregate intrinsic value of options exercised in the three months ended March 31, 2024 was \$0. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2024 were \$54,686 and \$0, respectively.

The following table summarizes the components of stock-based compensation expense included in the condensed consolidated statements of comprehensive income:

	Three Months Ended March 31,			
	2024		2023	
Stock-Based Compensation Expense:				
Cost of revenue	\$	781 \$	125	
Sales and marketing expense		3,027	431	
Research and development expense		4,503	701	
General and administrative expense		6,258	811	
	\$	14,569 \$	2,068	

	,	Three Months Ended March 31,			
	2024		2023		
Stock-based compensation expense by type:					
Employee stock purchase plan	\$	2,353 \$	2,018		
Non-employee stock purchase plan		9	11		
2019 and 2023 Subsidiary option grants		12,207	39		
	\$	14,569 \$	2,068		

NOTE 19 – INCOME TAXES

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period during which such rates are enacted.

The Company considers all available evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become realizable. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carry-forward periods) and projected taxable income in assessing the realizability of deferred tax assets. In making such judgments, significant weight is given to evidence that can be objectively verified.

As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. Prior to September 30, 2019, the Company had recorded a valuation allowance for the full amount of net deferred tax assets in the United States, as the realization of deferred tax assets was uncertain. Since September 30, 2019, the Company has not maintained a valuation allowance except for a partial valuation allowance on certain U.S. and foreign deferred tax assets. In order to recognize the remaining U.S. deferred tax assets that continue to be subject to a valuation allowance, the Company will need to generate sufficient U.S. taxable income in future periods before the expiration of the deferred tax assets governed by the tax code.

ACM Shanghai has shown a three-year historical cumulative profit and has projections of future income. As a result, the Company does not maintain a valuation allowance.

The Company accounts for uncertain tax positions in accordance with the authoritative guidance on income taxes under which the Company may only recognize or continue to recognize tax positions that meet a more likely than not threshold. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes.

The Company's effective tax rate differs from statutory rates of 21% for U.S. federal income tax purposes and 15% to 25% for Chinese income tax purposes due to the effects of the valuation allowance and certain permanent differences from book-tax differences, including stock based compensation, deemed dividend income under Subchapter F of the U.S. Internal Revenue Code of 1986, as amended (Subpart F), and global intangible low-taxed income (GILTI) inclusions, and R&D super deduction. As a result, the Company recorded income tax expense of \$4,369 and \$2,879 during the three months ended March 31, 2024 and 2023, respectively. The decrease in the Company's effective income tax rate for the three months ended March 31, 2024 compared to the same period of the prior year was primarily due to an increased benefit from certain permanent deductions in a foreign jurisdiction.

Under the change in Section 174 made by the Tax Cuts and Jobs Act of 2017 which became effective on January 1, 2022, the Company is required to capitalize, and subsequently amortize R&D expenses over fifteen years for research activities conducted outside of the U.S. The capitalization of overseas R&D expenses results in a significant increase in the Company's global intangible low-taxed income inclusion.

The Company had total unrecognized tax benefits of \$13,026 as of both March 31, 2024 and December 31, 2023. If recognized, the net impact to effective rate, after indirect offset, would be \$12,943. The Company did not expect any reversal of unrecognized tax benefits in the next 12 months. The Company will recognize interest and penalties, when they occur, related to uncertain tax provisions as a component of tax expense. For the three months ended March 31, 2024 and 2023, \$338 and \$284 of interest and penalties was recognized, respectively.

The Company is subject to taxation in the United States, state, and foreign jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any

net operating loss or credits. Certain tax years are subject to foreign income tax examinations by tax authorities until the statute of limitations expire.

The Company's four principal mainland China subsidiaries, ACM Shanghai, ACM Wuxi, ACM Beijing and ACM Lingang, are liable for mainland China corporate income taxes at the rates of 15%, 25%, 25% and 15%, respectively. Pursuant to the Corporate Income Tax Law of mainland China, ACM's mainland China subsidiaries generally would be liable for mainland China corporate income taxes as a rate of 25%. According to Guoshuihan 2009 No. 203, an entity certified as an "advanced and new technology enterprise" is entitled to a preferential income tax rate of 15%. ACM Shanghai was certified as an "advanced and new technology enterprise" is entitled to a preferential income tax rate of 15%. ACM Shanghai was certified as an "advanced and new technology enterprise" in 2012 and again in 2016, 2018, and 2021, with an effective period of three years and is expected to be recertified for future years in 2024. In 2022, ACM Shanghai was certified as an eligible integrated circuit production enterprise and was entitled to a preferential income tax rate of 12.5% from January 1, 2020 to December 31, 2022. Certain entities which meet requirements according to the Policy of the Lingang New area in China (Shanghai) Pilot Free Trade Zone are entitled to a preferential income tax rate of 15%. ACM Lingang was certified for this in 2021, and this preferential income tax rate is valid from January 1, 2020 until December 31, 2024.

Income tax expense was as follows:

	Three Months Ended March 31,		
	 2024	2023	
Total income tax expense	\$ (4,369) \$	(2,879)	

NOTE 20 – COMMITMENTS AND CONTINGENCIES

The Company leases offices under non-cancelable operating lease agreements. See Note 11 for future minimum lease payments under non-cancelable operating lease agreements with initial terms of one year or more.

As of March 31, 2024, the Company had \$24,285 of open capital commitments to construction contracts and had additional \$1,409 of capital investment commitments. As of December 31, 2023, the Company had \$30,936 of open commitments to construction contracts and had additional \$7,413 of capital investment commitments.

Covenants in ACM Lingang's Grant Contract for State-owned Construction Land Use Right in Shanghai City (Category of R&D Headquarters and Industrial Projects) with the China (Shanghai) Pilot Free Trade Zone Lingang Special Area Administration require, among other things, that ACM Lingang pay liquidated damages in the event that (a) it does not make a total investment (including the costs of construction, fixtures, equipment and grant fees) of at least RMB 450.0 million (\$62,600) or (b) within six years after the land use right is obtained, the Company does not (i) generate a minimum specified amount of annual sales of products manufactured on the granted land or (ii) pay to mainland China at least RMB 157.6 million (\$22,000) in annual total taxes (including value-added taxes, corporate income tax, personal income taxes, urban maintenance and construction taxes, education surcharges, stamp taxes, and vehicle and shipping taxes) as a result of operations in connection with the granted land.

As of March 31, 2024 and December 31, 2023, the Company had paid in total \$132,014 and \$116,932, respectively for its Lingang-related investments. The Construction Completion Milestone was required to be met by January 9, 2024 but was not achieved. However, ACM Lingang believes it will receive the refund without penalty based on its explanation to the respective regulatory authorities of logistics-related delays, and expects that it will meet the milestone before July 9, 2024. The Company cannot guarantee that ACM Lingang will achieve the missed milestone in 2024, or even if it does achieve the milestone in 2024, that it will be refunded some or all of the 20% portion of the performance deposit of RMB 2.5 million (\$0.4 million).

In the normal course of business, the Company is subject to contingencies, including legal proceedings and environmental claims arising out of the normal course of businesses that relate to a wide range of matters, including among others, contracts breach liability. The Company records accruals for such contingencies based upon the assessment of the probability of occurrence and, where determinable, an estimate of the liability. Management may consider many factors in

making these assessments including past history, scientific evidence and the specifics of each matter. Some of these contingencies involve claims that are subject to substantial uncertainties and un-estimable damages.

The Company's management has evaluated all such proceedings and claims that existed as of March 31, 2024 and December 31, 2023. In the opinion of management, no provision for liability nor disclosure was required as of March 31, 2024 related to any claim against the Company because: (a) there is not a reasonable possibility that a loss exceeding amounts already recognized (if any) may be incurred with respect to such claim; (b) a reasonably possible loss or range of loss cannot be estimated; or (c) such estimate is immaterial.

As of March 31, 2024, the Company had no outstanding legal proceedings.

NOTE 21 – SEGMENT INFORMATION

The Company identifies operating segments according to how the business activities are managed and evaluated. The Company's chief operating decision maker ("CODM") has been identified as ACM's Chief Executive Officer. The Company's operating segments include ACM Research and ACM Shanghai. As the Company is engaged in the developing, manufacture and sale of capital equipment to global semiconductor manufacturers, and each of the operating segments share similar economic and other qualitative characteristics, the results of the Company's operating segments are aggregated into one reportable segment.

For geographical reporting, revenue by geographic location is determined by the location of customers' facilities to which products were shipped. Longlived assets consist primarily of property, plant and equipment, land use right, and right-of-use assets and are attributed to the geographic location in which they are located.

Long-lived assets by geographic region as of the periods ended were as follows:

	March 31, 2024	December 31, 2023
Long-lived assets by geography:		
Mainland China	\$ 231,208 \$	209,725
Korea	11,630	12,190
United States	1,259	1,276
Total	\$ 244,097 \$	223,191

NOTE 22 – STATUTORY SURPLUS RESERVE

In accordance with mainland China's Foreign Enterprise Law, ACM Shanghai, ACM Lingang, and ACM Wuxi are required to make appropriation to reserve funds, comprising the statutory surplus reserve and discretionary surplus reserve, based on after-tax net income in accordance with generally accepted accounting principles of mainland China ("mainland China GAAP").

Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with mainland China GAAP until the reserve is equal to 50% of the entities' registered capital. The amount is calculated annually at the end of each calendar year. The balances of statutory reserve funds was \$30,060 as of both March 31, 2024 and December 31, 2023, and is presented as statutory surplus reserve on the Company's condensed consolidated balance sheets.



Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this report and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, or our Annual Report. The following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in Part I, Item 1A. "Risk Factors" in our Annual Report, as well as those discussed below and elsewhere in this report, particularly in the section titled "Item 1A – Risk Factors" in Part II below.

ACM Research, Inc., or ACM Research, is a Delaware corporation founded in California in 1998 to supply capital equipment developed for the global semiconductor industry. Since 2005, ACM Research has conducted its business operations principally through its subsidiary ACM Research (Shanghai), Inc., or ACM Shanghai, a limited liability corporation formed by ACM Research in the People's Republic of China, or mainland China, in 2005. Unless the context requires otherwise, references in this report to "our company," "our," "us," "we" and similar terms refer to ACM Research, Inc. and its subsidiaries, including ACM Shanghai, collectively.

Our principal corporate office is located in Fremont, California. We conduct a substantial majority of our product development, manufacturing, support and services in mainland China through ACM Shanghai. We perform, through a subsidiary of ACM Shanghai, additional product development and subsystem production in Korea, and we conduct, through ACM Research, sales and marketing activities focused on sales of ACM Shanghai products in North America, Europe and certain regions in Asia outside mainland China.

ACM Research is not a mainland China operating company, and we do not conduct our operations in mainland China through the use of a variable interest entity, or VIE, or any other structure designed for the purpose of avoiding mainland China legal restrictions on direct foreign investments in mainland China-based companies. ACM Research has a direct ownership interest in ACM Shanghai as the result of its holding 82.1% of the outstanding shares of ACM Shanghai. Stockholders of ACM Research may never directly own equity interests in ACM Shanghai. We do not believe that our corporate structure or any other matters relating to our business operations require that we obtain any permissions or approvals from the China Securities Regulatory Commission, the Cyberspace Administration of China, or any other mainland China central government authority in order to continue to list shares of Class A common stock of ACM Research on the Nasdag Global Select Market. This determination was based on the facts aforementioned and mainland China Company Law, mainland China Securities Law, cybersecurity regulations and other relevant laws, regulations and regulatory requirements in mainland China currently in effect. However, if this determination proves to be incorrect, then it could have a material adverse effect on ACM Research. See "Item IA. Risk Factors-Risks Related to International Aspects of Our Business-If any mainland China central government authority were to determine that existing mainland China laws or regulations require that ACM Shanghai obtain the authority's permission or approval to continue the listing of ACM Research's Class A common stock in the United States or if those existing mainland China laws and regulations, or interpretations thereof, were to change to require such permission or approval, or if we inadvertently conclude that permissions or approvals are not required, ACM Shanghai may be unable to obtain the required permission or approval or may only be able to obtain such permission or approval on terms and conditions that impose material new restrictions and limitations on operation of ACM Shanghai, either of which could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless" in our Annual Report.


The business of ACM Shanghai is subject to complex laws and regulations in mainland China that can change quickly with little or no advance notice. To date, beyond the COVID-19-related restrictions in 2022, we have not experienced such intervention or influence by mainland China central government authorities or a change in those authorities' rules and regulations that have had a material impact on ACM Shanghai or ACM Research.

In addition, in the ordinary course of business, ACM Shanghai is required to obtain certain operating permits and licenses necessary for it to operate in mainland China, including business licenses, certifications relating to quality management standards, import and export-related qualifications from customs, as well as environmental and construction permits, licenses and approvals relating to construction projects. We believe ACM Shanghai has all such required permits and licenses. However, from time to time mainland China government issues new regulations, which may require additional actions on the part of ACM Shanghai to comply. If ACM Shanghai does not, or is unable to, obtain any such additional permits or licenses, ACM Shanghai may be subjected to restrictions and penalties imposed by the relevant mainland China



regulatory authorities, and it could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless.

The following chart depicts our corporate organization as of March 31, 2024:



A detailed description of how cash is transferred through our organization is set forth under "Note 2 – Summary of Significant Accounting Policies – Cash and Cash Equivalents" to the Condensed Consolidated Financial Statements of this report.

The U.S. Holding Foreign Companies Accountable Act, or the HFCA Act, requires that the Public Company Accounting Oversight Board, or the PCAOB, determine whether it is unable to inspect or investigate completely registered public accounting firms located in a non-U.S. jurisdiction because of a position taken by one or more authorities in any non-U.S. jurisdiction. Under current regulations, if ACM Research were to be included on the SEC's "Conclusive list of issuers identified under the HFCA Act" for two consecutive years due to our independent auditor being located in a jurisdiction that does not allow for PCAOB inspections, the SEC would prohibit trading in our securities and this ultimately could cause our securities to be delisted in the U.S., and their value may significantly decline or become worthless. See "Item 1A. Risk Factors—Risks Related to International Aspects of Our Business —We could be adversely affected if we are unable to comply with legislation and regulations regarding improved access to audit and other information and audit inspections of accounting firms, including registered public accounting firms, such as our prior and current audit firms, operating in mainland China" in our Annual Report for more information.

In addition to the matters discussed above, we are also subject to a number of legal and operational risks associated with our corporate structure, including as the result of a substantial portion of our operations being conducted in mainland China. Consequences of any of those risks could result in a material adverse change in our operations or cause the value of ACM Research Class A common stock to significantly decline in value or become worthless. Please carefully read the information included in "Item 1A. Risk Factors" in our Annual Report, in particular the risk factors addressing the following issues:

• If any mainland China central government authority were to determine that existing mainland China laws or regulations require that ACM Shanghai obtain the authority's permission or approval to continue the listing of ACM Research's Class A common stock in the United States or if those existing mainland China laws and regulations, or interpretations thereof, were to change to require such permission or approval, or if we inadvertently conclude that permissions or approvals are not required, ACM Shanghai may be unable to obtain the required permission or approval or terms and conditions that impose material new restrictions and limitations on operation of ACM Shanghai, either of which could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless.

- Mainland China central government authorities may intervene in, or influence, ACM Shanghai's mainland China-based operations at any time, and those authorities' rules and regulations in mainland China can change quickly with little or no advance notice.
- The mainland China central government may determine to exert additional control over offerings conducted overseas or foreign investment in mainland China-based issuers, which could result in a material change in operations of ACM Shanghai and cause significant declines in the value of ACM Research Class A common stock, or make them worthless.

Past statements and regulatory actions by mainland China central government authorities with respect to the use of VIEs and to data security and antimonopoly concerns have not affected our ability to conduct our business operations in mainland China. For further information, see "Item 1A. Risk Factors —Risks Related to International Aspects of Our Business" in our Annual Report for more information.

Overview

We supply advanced, innovative capital equipment developed for the global semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use our wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. We have designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. We also develop, manufacture and sell a range of advanced packaging tools to wafer assembly and packaging customers.

Since 2009 we have delivered more than 850 tools to our customers, more than 705 of which were repeat orders or acceptances upon contractual performance obligations having been met and thereby generated revenue to us. The balance of the delivered tools is subject to the customer's acceptance of the tool upon the tool's satisfaction of applicable contractual requirements or subject to the customer's subsequent discretionary commitment to purchase the tool. To date, substantially all of our sales of equipment for semiconductor-manufacturing have been to customers located in Asia, and we anticipate that a substantial majority of our revenue from these products will continue to come from customers located in this region for the foreseeable future. We have begun to add to our efforts to further address customers in North America, Western Europe and Southeast Asia, by expanding our direct sales teams and increasing our global marketing activities.

Recent Developments

ACM Shanghai Proposed Dividend

In February 2024, ACM Research's principal operating subsidiary, ACM Shanghai (SSEC: 688082.SS), announced in a filing with the Shanghai Stock Exchange a proposal to pay a cash dividend of RMB 0.627 per share or an aggregate total of approximately RMB 273.2 million (approximately \$38.5 million) to the stockholders of ACM Shanghai. The proposed dividend is subject to approval by ACM Shanghai's stockholders at ACM Shanghai. It is possible that the proposed dividend may not be approved by ACM Shanghai's stockholders, or that ACM Shanghai may not pay the dividend, even if approved, and even if approved and paid, the net amount and the timing of any proceeds to be repatriated by ACM Research to the United States would be uncertain. If the proposed dividend is approved and paid, ACM Research estimates that it would intend to use the net proceeds, if any, for working capital and general corporate purposes.

ACM Shanghai Proposed Private Offering

In January 2024, ACM Research announced that ACM Shanghai intends to offer up to 43.6 million of its ordinary shares, subject to market conditions, the approval of ACM Shanghai's stockholders, completion of the review process by the Shanghai Stock Exchange, completion of the registration process by the China Securities Regulatory Commission, and other factors, in a private offering to qualified buyers, in compliance with the requirements of the China Securities Regulatory Commission, which would constitute up to 10% of ACM Shanghai's share capital prior to the transaction (the "Private Offering").

ACM Research estimates that if consummated in full, the proposed Private Offering would generate gross proceeds of up to RMB 4.5 billion (\$625 million) to ACM Shanghai, whose management would have broad discretion over the use of such proceeds. It is unlikely that any of such proceeds would be distributed to ACM Research, and that its equity interest in ACM Shanghai would decline from 82.1% to approximately 74.6%. As of March 31, 2024 and the date of this report, the proposed Private Offering has not been completed.

Mainland China Government Research and Development Funding

ACM Shanghai has received eight special government grants. The first grant, which was awarded in 2008, relates to the development and commercialization of 65nm to 45nm stress-free polishing technology. The second grant was awarded in 2009 to fund interest expense on short-term borrowings. The third grant was made in 2014 and relates to the development of electrocopper-plating technology. The fourth grant was made in June 2018 and related to development of polytetrafluoroethylene. The fifth grant was made in 2020, and relates to the development of other cleaning technologies. The sixth grant was made in 2020, and relates to the development of other cleaning technologies. The seventh grant was made in 2021, and relates to the development of the R&D and production center in the Lin-gang Special Area of Shanghai. These governmental authorities provide significant funding, although ACM Shanghai and ACM Research (Lingang), Inc., or ACM Lingang are also required to invest certain amounts in the projects. The eighth grant was made in 2022, and relates to the development of 300 mm cleaning and drying equipment

The governmental grants contain certain operating conditions, and we are required to go through a government due diligence process once the project is complete. The grants therefore are recorded as long-term liabilities upon receipt, although we are not required to return any funds ACM Shanghai receives. Grant amounts are recognized in our statements of comprehensive income as follows:

- Government subsidies relating to current expenses are recorded as reductions of those expenses in the periods in which the current expenses are recorded. For the three months ended March 31, 2024 and 2023, related government subsidies recognized as reductions of relevant expenses in the condensed consolidated statements of comprehensive income were \$0.4 million and \$0.5 million, respectively.
- Government subsidies related to depreciable assets are credited to income over the useful lives of the related assets for which the grant was received. For the three months ended March 31, 2024 and 2023, related government subsidies recognized as other income in the condensed consolidated statements of comprehensive income were \$81,000 and \$78,000, respectively.
- Government subsidies related to tax refund and others are recorded as other income in the periods as incurred. For the three months ended March 31, 2024 and 2023, related government subsidies recognized as other income in the condensed consolidated statements of comprehensive income were \$1.7 million and \$0.1 million, respectively.

Net Income Attributable to Non-Controlling Interests

In 2019 ACM Shanghai sold a total number of shares representing 8.3% of its outstanding ACM Shanghai shares, after which ACM Research held the remaining 91.7% of ACM Shanghai's outstanding shares. In 2021 ACM Shanghai sold a total number shares representing an additional 10% of its outstanding ACM Shanghai shares in its STAR IPO, after which ACM Research held the remaining 82.5% of ACM Shanghai's outstanding shares. However, in May 2023, ACM Research's ownership declined to 82.1% due to the exercise of 2,150,309 stock options related to ACM Shanghai shares. As a result, we reflect the portion of our net income allocable to the minority holders of ACM Shanghai shares as net income attributable to non-controlling interests.

Critical Accounting Policies and Estimates

In preparing our condensed consolidated financial statements in conformity with GAAP, we make assumptions, judgments and estimates in applying our accounting policies that can have a significant impact on our revenue, operating income and net income, as well as on the value of certain assets and liabilities on our condensed consolidated balance sheets. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. At least quarterly, we evaluate our assumptions, judgments and estimates and make changes as deemed necessary. Actual results could differ materially from these estimates under different assumptions or conditions.



We believe that the assumptions, judgments and estimates involved in the accounting for the following accounting policies have the greatest potential impact on our condensed consolidated financial statements, and we therefore consider these to be our critical accounting estimates. For information on our significant accounting policies, see Note 2 in the notes to condensed consolidated financial statements in Part I, Item 1 of this report and in the Notes to Condensed Consolidated Financial Statements in Part II, Item 8 of our Annual Report, describe the significant accounting policies and methods used in the preparation of the Company's condensed consolidated financial statements. There have been no material changes to the Company's critical accounting estimates included in our Annual Report.

Recent Accounting Pronouncements

A discussion of recent accounting pronouncements is included in our Annual Report and is updated in Note 2 to the condensed consolidated financial statements included in this report.

Results of Operations

The following table sets forth our results of operations for the periods presented, as percentages of revenue.

	Three Months E	nded March 31,
	2024	2023
Revenue	100.0 %	100.0 %
Cost of revenue	48.0	46.2
Gross margin	52.0	53.8
Operating expenses:		
Sales and marketing	9.3	12.6
Research and development	15.7	18.9
General and administrative	10.4	10.4
Total operating expenses, net	35.4	41.9
Income from operations	16.6	11.9
Interest income, net	0.6	1.5
Realized gain from sale of short-term investments	0.2	5.4
Unrealized loss on short-term investments	-1.7	-0.9
Other income (expense), net	2.0	-1.9
Loss from equity method investments	-0.3	-0.0
Income before income taxes	17.4	16.0
Income tax expense	-2.9	-3.9
Net income	14.5	12.1
Less: Net income attributable to non-controlling interests	3.0	2.4
Net income attributable to ACM Research, Inc.	11.5 %	9.7 %

Comparison of Three Months Ended March 31, 2024 and 2023

Revenue

	Three Months Ended March 31,						
		2024		2023	% Change 2024 v 2023	Al	osolute Change 2024 v 2023
		(in tho	isands)			
Revenue	\$	152,191	\$	74,256	105.0 %	\$	77,935
Single wafer cleaning, Tahoe and semi-critical cleaning equipment	\$	109,470	\$	36,614	199.0 %	\$	72,856
ECP (front-end and packaging), furnace and other technologies		25,800		26,598	(3.0)%		(798)
Advanced packaging (excluding ECP), services & spares		16,921		11,044	53.2 %		5,877
Total Revenue by Product Category	\$	152,191	\$	74,256	105.0 %	\$	77,935

The increase in revenue for three months ended March 31, 2024 as compared to the same period in 2023 reflects higher sales of single wafer cleaning, Tahoe and semi-critical cleaning equipment, and Advanced packaging (excluding ECP), services and spares, partly offset by lower ECP (front-end and packaging), furnace and other technologies. The increased demand from is due in part to a longer term commitment by our mainland China-based customers to increase production capacity to achieve a greater share of the global semiconductor market.

Cost of Revenue and Gross Margin

]	Three Months En	ded March 31,		
		2024	2023	% Change 2024 v 2023	Absolute Change 2024 v 2023
		(in thous	ands)		
Cost of revenue	\$	73,070 \$	5 34,270	113.2 %	\$ 38,800
Gross profit		79,121	39,986	97.9 %	39,135
Gross margin		52.0 %	53.8 %	(1.9)%	-186 bps

Cost of revenue and gross profit increased in the three months ended March 31, 2024 as compared to the corresponding period in 2023 due to the increased sales volume, partly offset by a decrease in gross margin. The decrease in gross margin versus the prior-year period was primarily due to revenue mix between product categories, net of a favorable impact from fluctuations in the RMB to U.S. dollar exchange rate. Gross margin may vary from period to period, primarily related to the level of utilization and the timing and mix of revenue. We expect gross margin to be between 40.0% and 45.0% for the foreseeable future, with direct manufacturing costs approximating 50.0% to 55.0% of revenue and overhead costs totaling 5.0% of revenue.

Operating Expenses

	1	nree Months I	lnaea N	larch 31,			
		2024		2023	% Change 2024 v 2023	Absolute 2024 v	0
		(in the	usands)				
Sales and marketing expense	\$	14,173	\$	9,337	51.8 %	\$	4,836
Research and development expense		23,918		14,029	70.5 %		9,889
General and administrative expense		15,798		7,758	103.6 %		8,040
Total operating expenses	\$	53,889	\$	31,124	73.1 %	\$	22,765

Sales and marketing expense increased in the three months ended March 31, 2024 as compared to the corresponding period in 2023, reflecting an increase of \$2.9 million due to increased costs for personnel, commissions, travel & entertainment and professional services, \$2.6 million in stock-based compensation, \$0.3 million in office and outside service, offset by a decrease of \$1.0 million from promotional tools.

Thurs Mansher Fridad Mansh 21

Sales and marketing expense consists primarily of:

- compensation of personnel associated with pre-sale and after-sale services and support and other sales and marketing activities, including stock-based compensation;
- sales commissions paid to independent sales representatives;
- fees paid to sales consultants;
- cost of trade shows;
- costs of tools built for promotional purposes for potential new customers;
- travel and entertainment; and
- allocated overhead for rent and utilities.

We expect that, for the foreseeable future, sales and marketing expenses will increase in dollars, as we incur additional costs associated with growing our customer base in mainland China and regions outside of mainland China.

Research and development expense increased in the three months ended March 31, 2024 as compared to the corresponding period in 2023, reflecting an increase of \$3.8 million in stock-based compensation, \$3.6 million in costs of components for tools built for product development purposes, \$2.7 million in R&D-related personnel costs and \$0.3 million outside service, offset by a \$0.5 million decrease in other R&D-related costs.

Research and development expense represented 15.7% and 18.9% of our revenue in the three months ended March 31, 2024 and 2023, respectively. Without reduction by grant amounts received from mainland China governmental authorities (see '-Mainland China Government Research and Development Funding"), gross research and development expense totaled \$24.4 million, or 16.0% of total revenue, in the three months ended March 31, 2024 as compared to \$14.5 million, or 19.6% of revenue, in the corresponding period in 2023.

Research and development expense consists primarily of:

- compensation of personnel associated with our research and development activities, including stock based compensation;
- costs of components and other research and development supplies;
- costs of tools built for product development purposes;
- travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration;
- amortization of costs of software used for research and development purposes; and
- allocated overhead for rent and utilities.



We expect that, for the foreseeable future, research and development expenses will increase in dollars, as we incur additional costs to expand our product portfolio to address additional production steps and expand our research and development team to new regions.

General and administrative expense increased in the three months ended March 31, 2024 as compared to the corresponding period in 2023, primarily reflecting a \$5.4 million increase in stock based compensation, a \$3.0 million in personnel and other costs related to general and administrative costs, and a \$0.9 million increase in allowance for credit losses, offset by \$1.2 million decrease in professional services expenses.

General and administrative expense consists primarily of:

- compensation of executive, accounting and finance, human resources, information technology, and other administrative personnel, including stock-based compensation;
- professional fees, including accounting and corporate legal and defense fees;
- other corporate expenses including insurance;
- allowance for credit losses; and
- allocated overhead for rent and utilities.

We expect that, for the foreseeable future, general and administrative expenses will increase in dollars, as we incur additional costs associated with growing our business, operating ACM Research, as a public company in the United States and operating ACM Shanghai as a public company in mainland China.

Interest income, net, Other Income, net

	TI	hree Months H	Ended	March 31,		
		2024		2023	% Change 2024 v 2023	olute Change 024 v 2023
		(in tho	usands)		
Interest income	\$	1,774	\$	1,785	(0.6)%	\$ (11)
Interest expense		(783)		(695)	12.7 %	(88)
Interest income, net	\$	991	\$	1,090	-9.1 %	\$ (99)
Other income (expense), net	\$	3,080	\$	(1,418)	-317.2 %	\$ 4,498

Interest income (expense), net consists of interest earned on our cash and cash equivalents, restricted cash accounts, and short-term and long-term time deposits, offset by interest expense incurred from outstanding short-term and long-term borrowings. Interest income (expense), net decreased in the three months ended March 31, 2024 as compared to the corresponding period in 2023, due to higher interest expense related to a higher balance of total borrowings.

Other income (expense), net primarily reflects (a) gain recognized from the impact of exchange rates on our working-capital which was \$1.4 million for the three months ended March 31, 2024 compared to \$1.5 million loss recognized from the impact of exchange rates on our working capital for the three months ended March 31, 2023, (b) government subsidies, as described under "—Mainland China Government Research and Development Funding" above, and other factors.

Realized gain and unrealized loss from short-term investment, and income (loss) from equity investments.

	,	Three Months E	nde	ed March 31,			
		2024		2023	% Change 2024 v 2023	Al	bsolute Change 2024 v 2023
Realized gain from sale of short-term investments	\$	273	\$	3,994	(93.2)%	\$	(3,721)
Unrealized loss on short-term investments	\$	(2,595)	\$	(654)	(296.8)%	\$	(1,941)
Loss from equity method investments	\$	(520)	\$	(32)	(1525.0)%	\$	(488)

We recorded a realized gain from sale of equity investment of \$0.3 million for the three months ended March 31, 2024 as compared to \$4.0 million in the prior-year period due to a sale of short-term investments (Note 15).

We recorded an unrealized loss on equity investment of \$2.6 million for the three months ended March 31, 2024 as compared to an unrealized loss of \$0.7 million for the same period in 2023, based on a change in market value of ACM Shanghai's short term investments (note 15).

Loss from equity investments increased by \$0.5 million for the three months ended March 31, 2024 due to an decrease of net income from investments in affiliates (Note 14).

Income Tax Expense

The following presents components of income tax expense for the indicated periods:

	Th	ree Months I	Ended Ma	rch 31,
	2	2024	2	2023
		(in tho	usands)	
Total income tax expense	\$	(4,369) \$ (2,879)		

We recognized a tax expense of \$4.4 million for the three months ended March 31, 2024 as compared to a tax expense of \$2.9 million for the prior year period. The tax expense for the three months ended March 31, 2024 primarily resulted from the tax effect of a decrease in our effective income tax rate applied to an increase in operating profit for the period. The decrease in our effective income tax rate for the three months ended March 31, 2023 compared to the same period of the prior year was primarily due to an increased benefit from certain permanent deductions in a foreign jurisdiction.

Our effective tax rate differs from statutory rates of 21% for U.S. federal income tax purposes and 12.5% to 25% for mainland China income tax purposes due to the effects of the valuation allowance and certain permanent differences as it pertains to book-tax differences in the treatment of stock-based compensation and non-U.S. research expenses. Our four mainland China subsidiaries, ACM Shanghai, ACM Wuxi, ACM Beijing, and ACM Lingang, are liable for mainland China corporate income taxes at the rates of 15%, 25%, 25%, and 15%, respectively. Pursuant to the Corporate Income Tax Law of mainland China, our mainland China subsidiaries generally would be liable for mainland China corporate income taxes at a rate of 25%. According to Guoshuihan 2009 No. 203, an entity certified as an "advanced and new technology enterprise" is entitled to a preferential income tax rate of 15%. ACM Shanghai was certified as an "advanced and new technology enterprise" is entitled to be re-certified for future years in 2024. In 2021, ACM Shanghai was certified as an eligible integrated circuit production enterprise and is entitled to a preferential income tax rate of 12.5% from January 1, 2020 to December 31, 2022. Certain entities which meet requirements according to the Policy of the Lingang New area in China (Shanghai) Pilot Free Trade Zone are entitled to a preferential income tax rate of 15%. ACM Lingang was certified for this in 2021, and this preferential income tax rate is valid from December 31, 2020 until December 31, 2024. We file income tax returns in the United States and state and foreign jurisdictions.



All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits. Certain tax years are subject to foreign income tax examinations by tax authorities until the statute of limitations expire.

Net Income Attributable to Non-Controlling Interests

	Т	hree Months Ended M	Iarch 31,		
		2024	2023	% Change 2024 v 2023	Absolute Change 2024 v 2023
		(in thousands)			
Net income attributable to non-controlling interests	\$	4,659 \$	1,818	156.3 %	\$ 2,841

ACM Research owns 82.1% of ACM Shanghai's (note 1) outstanding shares which is reflected in our condensed consolidated financial statements. We reflect the portion of net income allocable to the minority holders of ACM Shanghai shares as net income attributable to non-controlling interests.

Foreign currency translation adjustment

	Th	ree Months Ended	March 31,		
		2024	2023	% Change 2024 v 2023	Absolute Change 2024 v 2023
		(in thousands))		
Foreign currency translation adjustment	\$	(6,829) \$	9,423	(172.5)%	\$ (16,252)

We recorded a loss of foreign currency translation adjustment of (\$6.8 million) for the three months ended March 31, 2024, as compared to a gain of \$9.4 million for the same period in 2023, primarily based on the net effect of RMB to dollar exchange rate fluctuations for the period on the converted value of ACM Shanghai's RMB-denominated balances to U.S. dollar equivalents.

Comprehensive income attributable to non-controlling interests

	Т	hree Months Ende	d March 31,		
		2024	2023	% Change 2024 v 2023	Absolute Change 2024 v 2023
		(in thousan	ds)		
Comprehensive income attributable to non-controlling interests	\$	3,406 \$	3,462	(1.6)%	\$ (56)

Comprehensive income attributable to non-controlling interests for the three months ended March 31, 2024 is consistent with the three months ended March 31, 2023, reflecting a change in net income attributable to the non-controlling interests for the period together with the impact of foreign exchange rate fluctuations on the cumulative balance.



Liquidity and Capital Resources

During the first three months of 2024, we funded our technology development and operations principally through our beginning global cash balances, including the cash balances at ACM Shanghai, borrowings by ACM Shanghai from local financial institutions, and our loan from China CITIC Bank.

Cash and cash equivalents, restricted cash, short-term time deposits and long-term time deposits were \$288.3 million at March 31, 2024, compared to \$304.5 million at December 31, 2023. The (\$16.2 million) decrease was primarily driven by (\$9.6 million) of cash used in operations, (\$32.9 million), excluding net cash increase for time deposits, used in investing activities, \$26.8 million net cash provided by financing activities, and a (\$0.5 million) decline from the effect of exchange rate on cash, cash equivalents and restricted cash.

	Ν	1arch 31, 2024	Dec	cember 31, 2023		
		(In thousands)				
Cash and cash equivalents, restricted cash, and time deposits:						
Cash and cash equivalents and restricted cash	\$	212,113	\$	183,173		
Short-term time deposits		48,364		80,524		
Long-term time deposits		27,841		40,818		
Total	\$	288,318	\$	304,515		

Our future working capital needs beyond the next twelve months will depend on many factors, including the rate of our business and revenue growth, the payment schedules of our customers, the timing and magnitude of our capital expenditures, and the timing of investment in our research and development as well as sales and marketing. We believe our existing cash and cash equivalents and short-term and long-term time deposits, our cash flow from operating activities, and bank borrowings by us and ACM Shanghai will be sufficient to meet our anticipated cash needs within our longer term planning horizon.

ACM Shanghai has historically participated in certain mainland China government-sponsored grant and subsidy programs, as described under "—Mainland China Government Research and Development Funding" and "—Contractual Obligations" and we expect that ACM Shanghai will continue to take advantage of these programs when they are available and fit with our business strategy. ACM Shanghai generally applies for these grants and subsidies through the applicable mainland China government agency's defined processes. Periodically, the public relations department researches the availability of these grants and subsidies through mainland China government agencies with whom ACM Shanghai files business surveys and taxes. Management of ACM Shanghai then assesses which grants and subsidies for which ACM Shanghai may be eligible and submits the relevant application. The decision to award the grant to ACM Shanghai is made by the relevant mainland China government agencies based on suitability and the merits of the application. Neither ACM Research, nor ACM Shanghai or any of our other subsidiaries, has any direct relationship with any mainland China government agency, and our anticipated cash needs for the next twelve months neither anticipate, nor require, receipt of any mainland China government grants or subsidies.

To the extent our cash and cash equivalents, cash flow from operating activities and short-term bank borrowings are insufficient to fund our future activities in accordance with our strategic plan, we may determine to raise additional funds through public or private debt or equity financings or additional bank credit arrangements. We also may need to raise additional funds in the event we determine in the future to effect one or more acquisitions of businesses, technologies and products. If additional funding is necessary or desirable, we may not be able to obtain bank credit arrangements or to obtain an equity or debt financing on terms acceptable to us or at all.

Restrictions under mainland China laws and regulations as well as restrictions under ACM Shanghai's bank loan agreements, may significantly restrict ACM Shanghai's ability to transfer a portion of ACM Shanghai's net assets to ACM Research, other subsidiaries of ACM Research and to holders of ACM Research Class A common stock. See "Item 1A. Risk Factors – Regulatory Risks – Mainland China's currency exchange control and government restrictions on investment repatriation may impact our ability to transfer funds outside of mainland China, which could materially and adversely affect our ability to grow, make investments or acquisitions that could benefit our business, otherwise fund and conduct our business, or pay dividends on our common stock" in our Annual Report.

For the three months ended March 31, 2024 and 2023, with the exception of sales and services-related transfer-pricing payments in the ordinary course of business, no transfers, distributions have been made between ACM Research, and its subsidiaries, including ACM Shanghai, or to holders of ACM Research Class A common stock.

Our cash and cash equivalents at March 31, 2024 were held for working capital purposes and other potential investments. ACM Shanghai, our only direct mainland China subsidiary, is, however, subject to mainland China restrictions on distributions to equity holders. The use of proceeds raised by the STAR Market IPO, without further approvals, are limited to specific usage. Our accounts receivable balance fluctuates from period to period, which affects our cash flow from operating activities. Fluctuations vary depending on cash collections, client mix, and the timing of shipment and acceptance of our tools.

ACM Research has never declared or paid cash dividends on our capital stock. AMC Research intends to retain all available funds and any future earnings to support the operation of and to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future.

Cash Flow Used in Operating Activities. Net cash used in operating activities of (\$9.6 million) during the three months ended March 31, 2024 consisted of:

	Tł	Three Months Ended March 31			
		2024		2023	
		(In tho	isands)	
Net Income	\$	22,092	\$	8,963	
Non-cash operating lease cost		973		488	
Provision for inventory		1,025		306	
Provision for credit losses		1,171		298	
Depreciation and amortization		2,518		1,714	
Realized gain on short-term investment		(273)		(3,994)	
Loss from equity method investments		520		32	
Unrealized loss on short-term investments		2,595		654	
Deferred income taxes		(1,129)		(6,294)	
Stock-based compensation		14,569		2,068	
Net changes in operating assets and liabilities		(53,710)		(34,729)	
Net cash flow used in operating activities	\$	(9,649)	\$	(30,494)	

Significant net changes in operating asset and liability accounts primarily include the following uses of cash: an increase of inventories, net (\$38.6 million) (Note 5), an increase of accounts receivable of (\$15.3 million) (Note 4), and an increase in other assets (\$10.6 million) and the following sources of cash: a \$8.6 million increase on other liabilities and a \$2.2 million increase in customer advances.

Cash Flow Used in Investing Activities. Net cash used in investing activities, excluding net cash increase for time deposits, for the three months ended March 31, 2024 was (\$32.9 million), primarily consisting of (\$26.1 million) for purchase of property and intangible assets, (\$6.0 million) for purchase of long-term investments, and (\$1.4 million) for purchase of short-term investment (note 15), partly offset by \$0.6 million net dividends received from long term investments (note 14).

Cash Flow Provided by Financing Activities. Net cash provided by financing activities for the three months ended March 31, 2024 was \$26.8 million, primarily consisting of \$23.5 million net proceeds from short-term borrowing, and \$4.8 million proceeds from exercise of stock options, partly offset by (\$1.5 million) repayment of short-term and long-term borrowings.

We and ACM Shanghai, together with the subsidiaries of ACM Shanghai, have short-term and long-term borrowings with six banks, as follows:



Lender	Agreement Date	Maturity Date	Annual Interest Rate		Maximum Borrowing Amount(1)		mount Outstanding at March 31, 2024
					(in the		unds)
China CITIC Bank (2)	July 2023	Repayable by installments and the last installments repayable in December 2025	4.50%		RMB200,000		RMB100,000
				\$	28,180	\$	14,090
China Everbright Bank	July 2021	August 2024	3.00%		RMB150,000		RMB17,455
				\$	21,135	\$	2,459
Bank of China	September 2023	September 2024	2.87%		RMB40,000		RMB40,032
				\$	5,636	\$	5,640
China Merchants Bank	August 2023	September 2024	2.60%~3.00%		RMB200,000		RMB200,161
				\$	28,180	\$	28,203
Bank of China	March 2024	March 2025	2.75%		RMB120,000		RMB120,092
				\$	16,908	\$	16,921
China Merchants Bank	November 2020	Repayable by installments and the last installments repayable in November 2030	3.95%		RMB128,500		RMB91,694
				\$	18,106	\$	12,919
Bank of China	June 2021	Repayable by installments and the last installments repayable in June 2024	2.60%		RMB10,000		RMB7,505
				\$	1,409	\$	1,058
Bank of China	September 2021	Repayable by installments and the last installments repayable in September 2024	2.60%		RMB35,000		RMB26,259
				\$	4,932	\$	3,701
Bank of Shanghai	December 2022	October 2024	2.85%		RMB100,000		RMB100,079
<u> </u>				\$	14,090	\$	14,101
China CITIC Bank	August 2023	Repayable by installments and the last installments repayable in August,2025	3.10%		RMB100,000		RMB99,986
					RMB14,090	\$	14,088

Industrial Bank of Korea	December 2023	December 2024	4.27%	KRW2,000,000	KRW2,000,000
				\$ 1,483	\$ 1,483
				\$ 154,149	\$ 114,663

(1) Converted from RMB to dollars as of March 31, 2024. The loan from China Merchants Bank is secured by a pledge of the property of ACM Lingang and guaranteed by ACM Shanghai, as described above under "—Contractual Obligations."

(2) This China CITIC bank facility agreement is with ACM Research, Inc.

Effect of exchange rate changes on cash, cash equivalents and restricted cash. The effect of exchange rate cash, and cash equivalents was \$0.6 million during the first three months ended March 31, 2024. The impact of fluctuations of the RMB to U.S. dollar currency exchange rate on a significant balance of these items held in RMB-denominated accounts (Note 2) contributed to the change.

Contractual Obligations

Grant Contract for State-owned Construction Land Use Right in Shanghai City

In 2020 ACM Shanghai, through its wholly-owned subsidiary ACM Lingang, entered into a Grant Contract for State-owned Construction Land Use Right in Shanghai City (Category of R&D Headquarters and Industrial Projects), or the Grant Agreement, with the China (Shanghai) Pilot Free Trade Zone Lingang Special Area Administration, or the Grantor. ACM Lingang obtained rights to use approximately 43,000 square meters (10.6 acres) of land in the Lingang Heavy Equipment Industrial Zone of Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, or the Land Use Right, for a period of fifty years, commencing on the date of delivery of the land in July 2020, which we refer to as the Delivery Date.

In exchange for its land use rights, ACM Lingang paid aggregate grant fees of RMB 61.7 million (\$9.5 million), or the Grant Fees, and a performance deposit of RMB 12.3 million (\$1.9 million), which is equal to 20% of the aggregate grant fees, to secure its achievement of the following performance milestones:

- the start of construction within 6 months after the Delivery Date (60% of the performance deposit), or Construction Start Milestone;
- the completion of construction within 30 months after the Delivery Date (20% of the performance deposit), or Construction Completion Milestone; and
- the start of production within 42 months after the Delivery Date (20% of the performance deposit), or Production Start Milestone.

Upon satisfaction of a milestone, the portion of the performance deposit attributable to that milestone will be repayable to ACM Lingang within ten business days. If the achievement of any of the above milestones is delayed or abandoned, ACM Lingang may be subject to additional penalties and may lose its rights to both the use of the granted land and any partially completed facilities on that land.

The status of the performance milestones for the period ended March 31, 2024 is as follows:

- ACM Lingang achieved the Construction Start Milestone and 60% of the performance deposit was refunded to ACM Shanghai in 2020.
 - The Construction Completion Milestone was required to be met by January 9, 2024 but was not achieved. However, ACM Lingang believes it will receive the refund without penalty based on its explanation to the respective regulatory authorities of logistic-related delays, and expectations that it will meet the milestone before July 9, 2024. We cannot guarantee that ACM Lingang will achieve the missed milestone in 2024, or even if it does achieve the milestone in 2024, that it will be refunded some or all of the 20% portion of the performance deposit of RMB 2.5 million (\$0.4 million).



Contractual penalties in the case of a delay of Construction Completion Milestone:

- If ACM Lingang fails to complete the construction pursuant to the date agreed under the Grant Agreement or any extended completion date approved by the Grantor, ACM Lingang shall pay 50% of the deposit for timely completion of construction as liquidated damages;
- If ACM Lingang delays the completion for more than six months beyond the date agreed under the Grant Agreement, or beyond any
 extended completion date approved by the Grantor, it shall pay the total deposit for timely completion of construction as liquidated
 damages.
- If the delay is more than one year, the Grantor is entitled to terminate the Grant Agreement and take back the Land Use Right. In such case, the Grantor shall refund the Grant Fees for the remaining land use term after deducting the deposit agreed under the Grant Agreement and refund the deposit for timely commencement of production and relevant bank interests in full to ACM Lingang.
- The Production Start Milestone is now required to be met by January 9, 2025. The Production Start Milestone was originally required to be met prior to January 9, 2024, but due to COVID-related delays, ACM filed multiple requests for extensions, the latest of which was granted on July 7, 2023. We cannot guarantee that ACM Lingang will meet any extended deadline or be refunded this 20% portion of the performance deposit.

Contractual penalties in the case of a delay of Production Start Milestone:

- If ACM Lingang fails to commence production pursuant to the date agreed under the Grant Agreement or any extended commencement date approved by the Grantor, ACM Lingang shall pay the total deposit for timely commencement of production as liquidated damages;
- If ACM Lingang fails to commence production pursuant to the extended commencement of production date (more than six months beyond the production start milestone), the Grantor is entitled to terminate the Grant Agreement and take back the Land Use Right. In such case, the Grantor shall refund the Grant Fees for the remaining land use term after deducting the deposit agreed under the Grant Agreement to ACM Lingang.

In addition to the milestones, covenants in the Grant Agreement require that, among other things, ACM Lingang will be required to pay liquidated damages in the event that:

- (a) it does not make a total investment (including the costs of construction, fixtures, equipment and grant fees) of at least RMB 450.0 million (\$63.4 million). ACM Lingang shall pay the liquidated damages equal to the same proportion of the Grant Fees as the proportion of the actual shortfall amount of investment in the total agreed investment amount or the investment intensity.
- (b) within seven years after the Delivery Date, or prior to July 9, 2027, it does not (i) generate a minimum specified amount of annual sales of products manufactured on the granted land or (ii) pay at least RMB 157.6 million (\$22.2 million) in annual total taxes (including value-added taxes, corporate income tax, personal income taxes, urban maintenance and construction taxes, education surcharges, stamp taxes, and vehicle and shipping taxes) as a result of operations in connection with the granted land.

If the total tax revenue of the project fails to reach but is no less than 80% of the standard agreed under the Grant Agreement, ACM Lingang shall pay 20% of the actual shortfall amount of the tax revenue as liquidated damages. If the total tax revenue of the project fails to reach 80% of the standard agreed under the Grant Agreement within 1 month after the agreed date of reaching target production, the Grantor is entitled to terminate the Grant Agreement, take back the Land Use Right, and shall refund the Grant Fees for the remaining land use term to ACM Lingang.

If the Grant Agreement is terminated because of breach of any terms above, the Grantor shall take back the buildings, fixtures and auxiliary facilities on the land area and provide ACM Lingang with corresponding compensation according to the residual value of the buildings, fixtures and auxiliary facilities when they are taken back. The total cumulative investment of land, buildings and construction in progress related to ACM Lingang amounted to \$132.0 million and \$116.9 million at March 31, 2024 and December 31, 2023, respectively.



How We Evaluate Our Operations

We present information below with respect to four measures of financial performance:

- We define shipments of tools to include (a) a repeat shipment to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue upon shipment or delivery, and (b) a first-time shipment of a first tool to a customer on an approval basis, for which we may recognize revenue in the future if contractual conditions are met, or if a purchase order is received.
- We define "adjusted EBITDA" as net income excluding interest expense (net), income tax benefit (expense), depreciation and amortization, unrealized (gain) loss on short-term investments, and stock-based compensation. We define adjusted EBITDA to also exclude restructuring costs, although we have not incurred any such costs to date.
- We define "free cash flow" as net cash provided by operating activities less purchases of property and equipment (net of proceeds from disposals) and purchase of short-term and long-term investments.
- We define "adjusted operating income (loss)" as our income (loss) from operations excluding stock-based compensation.

These financial measures are not based on any standardized methodologies prescribed by accounting principles generally accepted in the United States, or GAAP, and are not necessarily comparable to similarly titled measures presented by other companies.

We have presented shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) because they are key measures used by our management and board of directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. We believe that these financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of the expenses eliminated in calculating adjusted EBITDA and adjusted operating income (loss) can provide useful measures for period-to-period comparisons of our core operating performance and that the exclusion of property and equipment purchases from operating cash flow can provide a usual means to gauge our capability to generate cash. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

Shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) are not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP.

Shipments

We consider shipments a key operating metric as it reflects the total value of products delivered to customers and prospective customers by our productive assets.

Shipments consist of two components:

- a shipment to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue when the tool is delivered; and
- a shipment to a customer of a type of tool that the customer is receiving and evaluating for the first time, in each case a first tool, for which we may recognize revenue at a later date, subject to the customer's acceptance of the tool upon the tool's satisfaction of applicable contractual requirements or subject to the customer's subsequent discretionary commitment to purchase the tool.

First tool shipments can be made to either an existing customer that has not previously accepted that specific type of tool in the past — for example, a delivery of a SAPS V tool to a customer that previously had received only SAPS II tools — or to a new customer that has never purchased any tool from us.

Shipments in the three months ended March 31, 2024 totaled \$245.6 million, as compared to \$89.2 million for the same periods in 2023. Repeat tool shipments in the three months ended March 31, 2024 totaled \$118.6 million, as compared to \$38.9 million for same periods in 2023. First tool shipments in the three months ended March 31, 2024 totaled \$127.0 million, as compared to \$50.3 million for the same periods in 2023.

The dollar amount attributed to a first tool shipment is equal to the consideration we expect to receive if any and all contractual requirements are satisfied and the customer accepts the tool, or if the customer subsequently determines in its discretion to purchase the tool. There are a number of limitations related to the use of shipments in evaluating our business, including that customers have significant, or in some cases total, discretion in determining whether to accept or purchase our tools after evaluation and their decision not to accept or purchase delivered tools is likely to result in our inability to recognize revenue from the delivered tools. "First tool" shipments reflect the value of incremental new products under evaluation delivered to our customers or prospective customers for a given period and is used as an internal key metric to reflect future potential revenue opportunity. The cumulative cost of "first tool" shipments under evaluation at customers which have not been accepted by the customer is carried at cost and reflected in finished goods inventory (see Note 5 to the condensed consolidated financial statements included in this report). "First tool" shipments exclude deliveries to customers for which ACM Research does not have a basis to expect future revenue.

Adjusted EBITDA

There are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest GAAP equivalent. Some of these limitations are:

- adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future;
- we exclude stock-based compensation expense from adjusted EBITDA and adjusted operating income (loss), although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
- the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;
- adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
- adjusted EBITDA does not reflect interest expense, or the requirements necessary to service interest or principal payments on debt;
- adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;
- adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; and
- adjusted EBITDA includes expense reductions and non-operating other income attributable to mainland China governmental grants, which may mask the effect of underlying developments in net income, including trends in current expenses and interest expense, and free cash flow includes mainland China governmental grants, the amount and timing of which can be difficult to predict and are outside our control.

The following table reconciles net income, the most directly comparable GAAP financial measure, to adjusted EBITDA:

	Three Months Ended March 31,							
	2024		20	23	% Change 2024 v 2023	Absolute Change 2024 v 2023		
		(in tho	usands)					
Adjusted EBITDA Data:								
Net Income	\$	22,092	\$	8,963	146.5 %	\$ 13,129		
Interest expense (income), net		(991)		(1,090)	-9.1 %	99		
Income tax expense		4,369		2,879	51.8 %	1,490		
Depreciation and amortization		2,518		1,714	46.9 %	804		
Stock based compensation		14,569		2,068	604.5 %	12,501		
Unrealized loss on short-term investments		2,595		654	296.8 %	1,941		
Adjusted EBITDA	\$	45,152	\$	15,188	197.3 %	\$ 29,964		

The increase in adjusted EBITDA for the three months ended March 31, 2024 as compared to the same period in 2023 reflects a \$13.1 million increase in net income, a \$12.5 million increase in stock based compensation, a \$0.8 million increase in depreciation and amortization, \$1.5 million impact from a change in income tax expense, \$1.9 million increase in unrealized loss on short-term investment, and other items.

We do not exclude from adjusted EBITDA expense reductions and non-operating other income attributable to mainland China governmental grants because we consider and incorporate the expected amounts and timing of those grants in incurring expenses and capital expenditures. If we did not receive the grants, our cash expenses therefore would be lower, and our cash position would not be affected, to the extent we have accurately anticipated the amounts of the grants. For additional information regarding our mainland China grants, please see "—Mainland China Government Research and Development Funding."

Free Cash Flow

The following table reconciles net cash used in operating activities, the most directly comparable GAAP financial measure, to free cash flow:

	Three Months Ended March 31,							
		2024		2023	% Change 2024 v 2023	A	bsolute Change 2024 v 2023	
		(in tho	usands))				
Free Cash Flow Data:								
Net cash used in operating activities	\$	(9,649)	\$	(30,494)	(68.4 %)	\$	20,845	
Purchase of property and equipment		(25,419)		(14,895)	70.7 %		(10,524)	
Purchase of short-term and long-term investments		(7,397)		(728)	916.1 %		(6,669)	
Free cash flow	\$	(42,465)	\$	(46,117)	(7.9 %)	\$	3,652	

The decrease in free cash flow for the three months ended March 31, 2024 as compared to the same period in 2023 reflected the factors driving net cash used in operating activities, an increase of purchases of property and equipment, and long-term investment. Consistent with our methodology for calculating adjusted EBITDA, we do not adjust free cash flow for the effects of mainland China government subsidies, because we take those subsidies into account in incurring expenses and capital expenditures. We do not adjust free cash flow for the effects of time-deposits, which for our internal purposes are considered as largely similar to cash.

Adjusted Operating Income

Adjusted operating income excludes stock-based compensation from income from operations. Although stock-based compensation is an important aspect of the compensation of our employees and executives, determining the fair value of certain of the stock-based instruments we utilize involves judgment and estimation and the expense recorded may bear little resemblance to the actual value realized upon the vesting or future exercise of the related stock-based awards. Furthermore, unlike cash compensation, the value of stock options, which is an element of our ongoing stock-based compensation in order to better understand the long-term performance of our core business and to facilitate comparison of our results to those of peer companies. The use of non-GAAP financial measures excluding stock-based compensation has limitations, however. If we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher and our cash holdings would be

less. The following tables reflect the exclusion of stock-based compensation, or SBC, from line items comprising income from operations:

			Т	hree Months F	End	ed March 31,		
		2024					2023	
	 Actual (GAAP)	SBC		Adjusted (Non- GAAP)		Actual (GAAP)	SBC	Adjusted on-GAAP)
				(in tho	usar	nds)		
Revenue	\$ 152,191	\$ -	\$	152,191	\$	74,256	\$ -	\$ 74,256
Cost of revenue	(73,070)	(781)		(72,289)		(34,270)	(125)	(34,145)
Gross profit	79,121	(781)		79,902		39,986	(125)	40,111
Operating expenses:								
Sales and marketing	(14,173)	(3,027)		(11,146)		(9,337)	(431)	(8,906)
Research and development	(23,918)	(4,503)		(19,415)		(14,029)	(701)	(13,328)
General and administrative	(15,798)	(6,258)		(9,540)		(7,758)	(811)	(6,947)
Income (loss) from operations	\$ 25,232	\$ (14,569)	\$	39,801	\$	8,862	\$ (2,068)	\$ 10,930

Adjusted operating income for the three months ended March 31, 2024 increased by \$28.9 million, as compared with the same period in 2023, due to a \$16.4 million increase in income from operations and a \$12.5 million increase in stock-based compensation expense.

Item 3. Quantitative and Qualitative Disclosures About Market Risks

Our market risks and the ways we manage them are summarized in the section captioned "Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report. There have been no material changes in the first three months of 2024 to our market risks or to our management of such risks.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, or the Exchange Act, as of March 31, 2024. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that our management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on such evaluation, and as a result of the material weakness in internal control over financial reporting described below, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2024, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Notwithstanding the material weakness in internal control over financial reporting described below, our management, including our Chief Executive Officer and Chief Financial Officer, believes that our consolidated financial statements included in this report present fairly, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented, in conformity with GAAP.

Changes in Internal Controls Over Financial Reporting

During the quarter ended March 31, 2024, we implemented a new enterprise resource planning ("ERP") system in mainland China utilized in the preparation of our consolidated financial statements. The implementation resulted in one material weakness in internal control over financial reporting described below. We believe we have developed an appropriate plan to remediate and have begun our remediation efforts related to the material weakness. Other than the material weakness and remediation efforts described below, there were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Material Weakness in Internal Control over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

During the quarter ended March 31, 2024, management identified a deficiency constituting a material weakness related to the design and implementation of information technology general controls ("ITGCs") related to the implementation of our new ERP system in mainland China utilized in the preparation of our consolidated financial statements. Specifically, we did not (1) establish and maintain adequate pre-approval policy and process for the system changes; and (2) maintain a complete system change log.

Although the material weakness identified above did not result in any material misstatement of our consolidated financial statements, there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. Accordingly, management has concluded that this deficiency constitutes a material weakness and that as of March 31, 2024 our internal control over financial reporting was not effective.

Remediation Efforts

We have begun the process of, and are focused on, designing and implementing effective internal control measures to improve our internal control over financial reporting and remediate the material weakness. Our remediation efforts include the following:

- Corporate Governance and Oversight: We have established a plan to help stabilize the ERP system and correct the identified control deficiency. Additionally, we have engaged an outside professional firm to assist management overseeing the efforts to design, implement and ensure the ongoing execution of our ITGCs of the ERP system.
- Change Management: We will continue designing and implementing an improved process for requesting, testing, authorizing, and reviewing
 system changes. This implementation will include enabling a complete activity logs of accessing and/or making changes to the system and the
 addition of detection controls which will include the review of such activity logs. We are also establishing policies and process surrounding the
 testing, approval and implementation of system changes to ERP system.
- End User Training: We will also enhance the training of our personnel regarding their roles and responsibilities within the ITGCs objectives and activities.

We have shared this plan with our Audit Committee and will provide periodic updates with respect to our progress. The material weakness will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time for management to conclude, through testing, that the controls are operating effectively.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings or may be subject to claims arising in the ordinary course of our business. Although the results of these proceedings and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

Except as set forth below, there were no material changes to the risk factors discussed in Item 1A. "Risk Factors" of Part I in our Annual Report. In addition to the other information set forth in this report, you should carefully consider those risk factors, which could materially affect our business, financial condition and future operating results. Those risk factors are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition and operating results.

Risks Related to Ownership of Class A Common Stock

Our management identified a material weakness in our internal control over financial reporting that, if not properly remediated, could result in material misstatements in our consolidated financial statements that could cause investors to lose confidence in our reported financial information and have a negative effect on the trading price of our stock.

Effective internal control over financial reporting is necessary for us to provide accurate financial information. The Sarbanes-Oxley Act requires us to, among other things, evaluate the effectiveness of our internal control over financial reporting. As further discussed in "Item 4. Controls and Procedures" of Part I of this report, our internal controls over financial reporting were not effective as of March 31, 2024 due to the existence of a material weakness in such controls.

As of, and for the quarter ended, March 31, 2024, we identified a material weakness in our internal control over financial reporting related to the design and implementation of information technology general controls related to the implementation of our new enterprise resource planning system in mainland China utilized in the preparation of our consolidated financial statements. Specifically, we did not (1) establish and maintain adequate pre-approval policy and process for the system changes; and (2) maintain a complete system change log. As of March 31, 2024, we determined that the above mentioned material weakness had not been remediated.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The process of designing and implementing effective internal controls and procedures and remediating the material weakness will be a continual effort that may require us to expend significant resources to establish and maintain a system of controls that is adequate to satisfy our reporting obligations as a public company. We cannot assure you that the measures we take will be sufficient to remediate the material weakness or that we will implement and maintain adequate controls over our financial processes and reporting in the future in order to avoid additional material weaknesses or control or significant deficiencies occur in the future, we may be unable to report our financial results accurately or on a timely basis, which could cause our reported financial results to be materially misstated and result in the loss of investor confidence and cause the trading price of Class A common stock to decline. Moreover, ineffective controls could significantly hinder our ability to prevent fraud. For further information, see "Item 4. Controls and Procedures" of Part II of this report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2024, ACM Research issued, pursuant to the exercise of stock options at a per share exercise price of 0.50 per share, an aggregate of 275,740 shares of Class A common stock that were not registered under the Securities Act of 1933, as amended. We believe the offer and sale of those shares were exempt from registration under the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof (or Regulation D promulgated thereunder) because they did not involve a public offering. The recipients of the shares acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were recorded with respect to the shares. The recipients of the shares were accredited investors under Rule 501 of Regulation D.

Sale Date	Exercised Shares (Net)
January 3, 2024	27,033
March 1, 2024	34,434
March 1, 2024	177,089

March 5, 2024	9,843
March 5, 2024	27,341
Total	275,740

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

Rule 10b5-1 Trading Plans

On March 7, 2024, Jian Wang, Chief Executive Officer and President of ACM Shanghai, adopted a Rule 10b5-1 trading arrangement (the "Wang Plan") that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The Wang Plan allows for the contemporaneous exercise of options and sale of up to 120,000 shares of Class A common stock, at specific market prices, commencing on June 6, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii) December 31, 2024, or (iii) such date that the Wang Plan is otherwise terminated according to its terms, whichever comes first.

On March 7, 2024, Mark McKechnie, Chief Financial Officer of ACM Research, adopted a Rule 10b5-1 trading arrangement (the "McKechnie Plan") that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The McKechnie Plan allows for the contemporaneous exercise of options and sale of up to 81,516 shares of Class A common stock, at specific market prices, commencing on June 6, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii) December 31, 2025, or (iii) such date that the McKechnie Plan is otherwise terminated according to its terms, whichever comes first.

On March 14, 2024, Lisa Feng, Chief Financial Officer of ACM Shanghai, adopted a Rule 10b5-1 trading arrangement (the "Feng Plan") that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The Feng Plan allows for the contemporaneous exercise of options and sale of up to 30,000 shares of Class A common stock, at specific market prices, commencing on June 13, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii) June 4, 2025, or (iii) such date that the Feng Plan is otherwise terminated according to its terms, whichever comes first.

Item 6. Exhibits

The following exhibits are filed as part of this report:

Exhibit No.	Description
<u>31.01</u>	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
<u>31.02</u>	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
<u>32.01</u>	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 8, 2024

ACM RESEARCH, INC.

By: /s/ Mark McKechnie

Mark McKechnie Chief Financial Officer, Executive Vice President and Treasurer (Principal Financial Officer)

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David H. Wang, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of ACM Research, Inc.
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report.
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:
- (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024

/s/ David H. Wang

David H. Wang Chief Executive Officer and President (Principal Executive Officer)

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McKechnie, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of ACM Research, Inc.
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report.
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:
- (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
- (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024

/s/ Mark McKechnie

Mark McKechnie Chief Financial Officer, Executive Vice President and Treasurer (*Principal Financial Officer*)

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ACM Research, Inc. for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge on the date hereof:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of ACM Research, Inc. for the period presented therein.

Date: May 8, 2024

/s/ David H. Wang David H. Wang Chief Executive Officer and President

(Principal Executive Officer)

Date: May 8, 2024

/s/ Mark McKechnie

Mark McKechnie Chief Financial Officer, Executive Vice President and Treasurer (Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.